<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006535</article-id><article-id pub-id-type="pmc">PMC11859854</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020168</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Emulgel Containing Metronidazole and Clindamycin for the Treatment of Rosacea</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Grau-Bassal</surname><given-names>Guillermo</given-names></name><xref rid="af1-pharmaceutics-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4989-4821</contrib-id><name><surname>Calpena-Campmany</surname><given-names>Ana Cristina</given-names></name><xref rid="af2-pharmaceutics-17-00168" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00168" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9906-049X</contrib-id><name><surname>Silva-Abreu</surname><given-names>Marcelle</given-names></name><xref rid="af2-pharmaceutics-17-00168" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00168" ref-type="aff">3</xref><xref rid="c1-pharmaceutics-17-00168" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9238-187X</contrib-id><name><surname>Su&#x000f1;er-Carb&#x000f3;</surname><given-names>Joaquim</given-names></name><xref rid="af2-pharmaceutics-17-00168" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00168" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9316-8459</contrib-id><name><surname>Mallandrich-Miret</surname><given-names>Mireia</given-names></name><xref rid="af2-pharmaceutics-17-00168" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00168" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7394-3438</contrib-id><name><surname>Mart&#x000ed;nez-Ruiz</surname><given-names>Sergio</given-names></name><xref rid="af4-pharmaceutics-17-00168" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Cordero</surname><given-names>Cecilia</given-names></name><xref rid="af4-pharmaceutics-17-00168" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Del Pozo</surname><given-names>Alfonso</given-names></name><xref rid="af2-pharmaceutics-17-00168" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5363-3125</contrib-id><name><surname>Febrer</surname><given-names>N&#x000fa;ria Bozal-de</given-names></name><xref rid="af1-pharmaceutics-17-00168" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cirri</surname><given-names>Marzia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00168"><label>1</label>Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farm&#x000e0;cia i Ci&#x000e8;ncies de l&#x02019;Alimentaci&#x000f3;, Universitat de Barcelona (UB), 08028 Barcelona, Spain; <email>gdegrau@ub.edu</email> (G.D.G.-B.); <email>nuriabozaldefebrer@ub.edu</email> (N.B.-d.F.)</aff><aff id="af2-pharmaceutics-17-00168"><label>2</label>Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain; <email>anacalpena@ub.edu</email> (A.C.C.-C.); <email>jsuner@ub.edu</email> (J.S.-C.); <email>mireia.mallandrich@ub.edu</email> (M.M.-M.); <email>apozo@ub.edu</email> (A.D.P.)</aff><aff id="af3-pharmaceutics-17-00168"><label>3</label>Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain</aff><aff id="af4-pharmaceutics-17-00168"><label>4</label>Departament de Bioqu&#x000ed;mica i Fisiologia, Facultat de Farm&#x000e0;cia i Ci&#x000e8;ncies de l&#x02019;Alimentaci&#x000f3;, Universitat de Barcelona, 08028 Barcelona, Spain; <email>sergio_martinez_ruiz@ub.edu</email> (S.M.-R.); <email>corderocecilia16@gmail.com</email> (C.C.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00168"><label>*</label>Correspondence: <email>silvadeabreu@ub.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>168</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Rosacea is a common skin condition with quite a relevance. It currently affects at least 10% of the European population at some point after the age of 30. It is a chronic disorder that mainly affects the skin on the face and is characterized by outbreaks and remissions. Under normal circumstances, the skin face presents a wide range of commensal organisms, such as <italic toggle="yes">Staphylococcus epidermidis</italic> or <italic toggle="yes">Demodex folliculorum</italic>, but dysbiosis of the skin flora plays a relevant role in inflammatory processes and the development of the disease. Metronidazole (MD) is one of the main treatments indicated to reduce redness on the cheeks, nose, chin, or forehead and also to treat flushing, erythema, pimples, and other symptoms due in part to its anti-inflammatory action. On the other hand, clindamycin (CM) is another antibiotic used for rosacea, especially for its action against anaerobic and Gram-positive bacteria. <bold>Background/Objectives</bold>: This study aimed to develop an emulgel formulation that includes MD and CM, using excipients with non-comedogenic and non-irritating properties. <bold>Methods</bold>: The formulation was characterised physiochemically, rheological measurements were made, and short-term stability studies were carried out. In vitro release, permeation studies, toxicity an in vitro inflammation model were evaluated in a HaCaT cell model. To determine the interaction between the antibiotics, the minimum inhibitory concentration was determined separately and together using the broth microdilution method. To determine the formulation&#x02019;s antimicrobial activity, an agar diffusion method was used. <bold>Results:</bold> The MD-CM-gel droplet size was measured by laser diffraction and the diameter obtained was less than 2.68 &#x000b1; 0.18 &#x000b5;m in 50% of the particles. Suitable results was observed for the short-term stability. Release and permeation data revealed sustained drug release and adequate permeation through human skin. Non-toxicity was detected and the MD showed an anti-inflammatory effect with non-interference of CM. Also, there is no antagonism between the two antibiotics and the MD-CM-gel shows better results when compared to the formulations with the antibiotics separately and to commercial formulations. <bold>Conclusions</bold>: It is suggested that, following detailed preclinical and clinical studies, MD-CM-gel could be considered as an alternative for treating rosacea.</p></abstract><kwd-group><kwd>rosacea</kwd><kwd>clindamycin</kwd><kwd>metronidazole</kwd><kwd>emulgel</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00168"><title>1. Introduction</title><p>Rosacea is a chronic inflammatory skin disease that affects an estimated 5% to 46% of the adult population, particularly those over 30 years of age [<xref rid="B1-pharmaceutics-17-00168" ref-type="bibr">1</xref>]. Redness, papules, pustules, telangiectasias, flushing episodes, and erythema are some of the symptoms that can appear, particularly in the central area of the face. It is common for an individual to present multiple symptoms simultaneously [<xref rid="B2-pharmaceutics-17-00168" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00168" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00168" ref-type="bibr">4</xref>]. Rosacea is classified into different subtypes based on these symptoms: erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea [<xref rid="B5-pharmaceutics-17-00168" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00168" ref-type="bibr">6</xref>]. The exact cause of rosacea remains unclear; however, several factors are considered potential contributors. These include alcohol consumption, certain medications or foods, sun exposure, emotional stress, chronic vasodilation, and inflammatory changes [<xref rid="B7-pharmaceutics-17-00168" ref-type="bibr">7</xref>]. Additionally, the presence of microorganisms, such as certain skin commensal bacteria and the mite Demodex follicularum, has been noted in rosacea patients [<xref rid="B8-pharmaceutics-17-00168" ref-type="bibr">8</xref>]. This disease affects the skin and can lead to dysbiosis, which can increase the population of certain microorganisms [<xref rid="B9-pharmaceutics-17-00168" ref-type="bibr">9</xref>]. It is not clear that microorganisms are the cause of rosacea. However, some of these, such as <italic toggle="yes">Stahpyloccocus epidermidis</italic> or <italic toggle="yes">Cuticubabacterium acnes</italic>, can activate the immune system via Toll-like receptors [<xref rid="B10-pharmaceutics-17-00168" ref-type="bibr">10</xref>].</p><p>Treatments usually include anti-inflammatories, skin care, sunscreens, retinoids, antibiotics, laser treatments, and surgical techniques. The type of rosacea that is impacted determines which therapies are appropriate. Erythematotelangiectatic and papulopustular rosacea are usually treated with topical treatments, such as metronidazole (MD) or azelaic acid. In contrast, others such as phymatosa are treated orally or with lasers or electrosurgery; in the case of ocular rosacea, the treatment is mainly with artificial tears [<xref rid="B11-pharmaceutics-17-00168" ref-type="bibr">11</xref>]. Moreover, topical treatments to reduce the inflammation or the intensity of symptoms, such as MD and other topical antibiotics, are also being used, including clindamycin (CM) [<xref rid="B12-pharmaceutics-17-00168" ref-type="bibr">12</xref>].</p><p>MD is a synthetic antibiotic derived from azomycin and produced by bacteria of the genus Actinobacteria and Proteobacteria. It can be administered in various ways, intravenously, vaginally, or orally, although the topical route is the most used to treat rosacea [<xref rid="B13-pharmaceutics-17-00168" ref-type="bibr">13</xref>]. Topical MD is effective in reducing the symptoms of rosacea, especially when administered at 0.75% in formulations with a high water content, such as creams and gels [<xref rid="B14-pharmaceutics-17-00168" ref-type="bibr">14</xref>]. Topical treatment with MD was first used in the 1980s and it was observed that its effect was due to its ability to reduce reactive oxygen species produced by neutrophils during inflammation [<xref rid="B15-pharmaceutics-17-00168" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00168" ref-type="bibr">16</xref>].</p><p>CM is another antibiotic used in the treatment of rosacea. It is powerful in lowering symptoms, and its effect, like different antibiotics, is unclear. It may be due to a direct effect on microorganisms, or it may be related to the reduction in inflammation. In these treatments, increased irritation has been observed in some cases, probably due to the components for its delivery [<xref rid="B17-pharmaceutics-17-00168" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00168" ref-type="bibr">18</xref>].</p><p>Ointments, creams, lotions, and gels are some examples of topical dosage forms. These have many disadvantages, such as stickiness, stability problems, and poor spreadability; they could also cause allergic reactions and sometimes show poor permeability and absorption [<xref rid="B19-pharmaceutics-17-00168" ref-type="bibr">19</xref>]. However, emulsions are easy to remove, spreadable, thixotropic, non-greasy, have a pleasant appearance, are emollient, and have a long shelf life. Nowadays, emulgels are used to deliver many drugs, such as analgesics, anti-inflammatories, anti-acne, and antifungals. It is therefore of great pharmacological importance and is relatively free of side effects [<xref rid="B20-pharmaceutics-17-00168" ref-type="bibr">20</xref>].</p><p>Emulgels are an emerging topical drug delivery system that combines the properties of emulsions and gels. For rosacea, it can be advantageous since it allows the incorporation of both hydrophilic and hydrophobic drugs, potentially improving the effectiveness of treatments. They also tend to have better stability and patient compliance compared to traditional creams or ointments [<xref rid="B21-pharmaceutics-17-00168" ref-type="bibr">21</xref>].</p><p>This is the first type of study that investigates the efficacy of MD and CM in the treatment of rosacea. Therefore, this study aims to develop an emulgel formulation incorporating MD and CM, along with mild excipients, emollients, and non-comedogenic agents. The formulation undergoes physicochemical characterization, evaluation of biopharmaceutical properties, and assessment of toxicity and efficacy in vitro using a HaCaT cell line inflammation model, as a potential treatment for rosacea.</p></sec><sec id="sec2-pharmaceutics-17-00168"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00168"><title>2.1. Materials</title><p>MD and CM were purchased from Acofarma (Barcelona, Spain); glycerine was obtained from Comercial Qu&#x000ed;mica Mass&#x000f3; (Barcelona, Spain); Simulgel<sup>&#x000ae;</sup> 600 (acrylamide/sodium acryloyldimethyl taurate copolymer and isohexadecane and polysorbate 80) was acquired from SEPPIC (Madrid, Spain); MCT (medium-chain triglycerides) were purchased from Fagron (Terrassa, Spain); isohexadecane was supplied by Inquiaroma (Barcelona, Spain); Phenotip<sup>&#x000ae;</sup> (phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) butylparaben (and) isobutylparaben) was obtained from Clariant (Leeds, UK). Potassium dihydrogen phosphate, methanol, and acetonitrile were supplied by Panreac (Madrid, Spain). Muller-Hinton broth, Muller-Hinton agar, tryptone soya broth, tryptona soya agar, and yeast extract powder were obtained from Oxoid Sigma-Aldrich (Madrid, Spain). Reagents used in the analytical method and sample analysis were acquired from Panreac (Barcelona, Spain); a Millipore Milli-Q purification system (Millipore Corporation, Burlington, MA, USA) provided the purified water used in this work. All other chemicals and reagents used in the study were of analytical grade. Nylon membranes, with a molecular weight cutoff at 12,000&#x02013;14,000 Da, were acquired from Iberlabo (Madrid, Spain).</p></sec><sec id="sec2dot2-pharmaceutics-17-00168"><title>2.2. Emulgel Preparation</title><p>Following the recommendations of the clinical practice in the association of MD to topical antibiotics, an emulgel was developed containing the combination of MD and CM. The composition of the emulgel is shown in <xref rid="pharmaceutics-17-00168-t001" ref-type="table">Table 1</xref>.</p><p>The emulgel consists of two phases: The aqueous phase was prepared by adding MD and CM in water and glycerine, and then, the solution was mixed with a paddle stirrer at 250 r.p.m. for 15 min. Separately, the oily phase was composed of Simulgel<sup>&#x000ae;</sup> 600, MCT, isohexadecane, and Phenonip<sup>&#x000ae;</sup>. The ingredients were mixed in a paddle stirrer at 250 r.p.m. for 15 min. The aqueous phase was added slowly to the oily phase, avoiding air formation in the emulsion. Then, it was mixed with the paddle stirrer for 30 min at 350 r.p.m. And finally, it was homogenized by Ultra-Turrax T50- (Ika Laborteknik, Staufen, Germany) at the lowest speed for 1 min to form the emulgel (MD-CM-gel). A free-drug emulgel was also prepared for microbiological study, as mentioned above. <xref rid="pharmaceutics-17-00168-f001" ref-type="fig">Figure 1</xref> depicts the preparation of MD-CM-gel.</p></sec><sec id="sec2dot3-pharmaceutics-17-00168"><title>2.3. Physicochemical Characterization of the Emulgel</title><sec id="sec2dot3dot1-pharmaceutics-17-00168"><title>2.3.1. Organoleptic Characteristics</title><p>The product should be white, bright with a uniform texture, and lump-free. The emulgel was visually observed for phase separation, creaming, exudate, colour changes, or any sign of destabilization.</p></sec><sec id="sec2dot3dot2-pharmaceutics-17-00168"><title>2.3.2. Stability Study and Optical Microscopy</title><p>Several aliquots of the product were stored in 100 mL Unguator<sup>&#x000ae;</sup> flasks for the stability study. During time 0, 3, and 6 months, the storage conditions were room temperature 25 &#x000b1; 2 &#x000b0;C. These samples were used to evaluate the visual appearance, and pH was measured by the pH meter CRISON micro-pH 2000 (Crison Instruments S.A., Alella, Spain).</p><p>The morphology of emulgel formulation was observed by a microscope (Model DM 1000 LED; Leica Microsystems) with image acquisition (Model EC; Leica Microsystems). The droplet size should be below 20 &#x000b5;m diameter.</p></sec><sec id="sec2dot3dot3-pharmaceutics-17-00168"><title>2.3.3. Surface Spreadability</title><p>The surface spreadability of the emulgel was assessed as the increase in the surface of a given amount of the formulation when increasing weights were applied at defined time points. The spreadability was conducted by an extensometer (26). On 0.35 g of formulation, the following weights were applied for 1 min: 26.06; 36.06; 46.06; 76.06; 126.06; 146.06; 176.06, and 226.06 g. Measurements were conducted after freshly prepared emulgel. The expansion in diameter was recorded as a function of the weight applied. Each measurement was estimated according to Equation (1):<disp-formula id="FD1-pharmaceutics-17-00168"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#x000d7;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">S</italic> is the surface spreading area (mm<sup>2</sup>) computed from the utilised mass of sample (g), and d is the average diameter (mm) impacted by the sample. Experimental results were analysed according to the best kinetic model and fitted to different mathematical models with the statistical program using GraphPad Prism<sup>&#x000ae;</sup> 10.2.3. The <italic toggle="yes">r</italic> value confirmed the model fitting.</p></sec><sec id="sec2dot3dot4-pharmaceutics-17-00168"><title>2.3.4. Droplet Size Measurement </title><p>The droplet size was determined by Mastersizer<sup>&#x000ae;</sup> 2000 (Malvern Instruments, Worcestershire, UK) using laser diffraction at 25 &#x000b0;C. Milli-Q water was used as a dispersant, yielding the relative distribution of the volume of droplets. The range of size classes was determined according to the Mie theory. Measurements were collected at room temperature (mean &#x000b1; SD, n = 3) over time up to 6 months. The results were processed by the software Mastersizer<sup>&#x000ae;</sup> 2000 version 5.6 (32).</p></sec><sec id="sec2dot3dot5-pharmaceutics-17-00168"><title>2.3.5. Rheological Behavior</title><p>Rheological rotational measurements were performed using a Haake Rheostress<sup>&#x000ae;</sup> 1 rheometer (Thermo Fisher Scientific, Karlsruhe, Germany). For all of measurements, the device was connected to the thermostatic circulator Thermo<sup>&#x000ae;</sup> Haake Phoenix II + Haake C25P and a computer PC provided with Haake Rheowin<sup>&#x000ae;</sup> Job Manager v. 4.91 software (Thermo Electron Corporation, Karlsruhe, Germany) to execute the tests and Haake Rheowin<sup>&#x000ae;</sup> Data Manager v. 4.91 software (Thermo Electron Corporation, Karlsruhe, Germany) to perform the analyses of the obtained data. Steady-state measurements were addressed with cone-and-plate geometry (0.105 mm gap) with a fixed lower plate and a mobile upper cone Haake C60/2&#x000b0; Ti (60 mm diameter, 2&#x000b0; angle). The shear stress (&#x003c4;) was measured as a function of the shear rate (&#x003b3;). Viscosity curves (&#x003b7; = f(&#x003b3;)) and flow curves (&#x003c4; = f(&#x003b3; &#x000b7;)) were recorded at 25 &#x000b1; 0.1 &#x000b0;C. The shear rate ramp program included a 3 min upward flow curve period from 0.1 to 100 s<sup>&#x02212;1</sup>, a 1 min constant shear rate period at 100 s<sup>&#x02212;1</sup>, and finally, a 3 min downward flow curve period from 100 to 0.1 s<sup>&#x02212;1</sup>. Data from the flow curves were fitted using mathematical models to identify the model that provided the best overall match of the experimentally observed rheological data: Bingham, Ostwald de Waele, Herschel-Bulkley, Casson, and Cross. The adequacy of the rheological profiles to the mathematical models was based on the correlation coefficient value (r) and chi-square value. The determination of the disturbance of the microstructure during the test or apparent thixotropy (Pa/s) was evaluated by the determination of the area of the hysteresis loop. Steady-state viscosity (&#x003b7;, Pa.s) was determined from the constant share section at 100 s<sup>&#x02212;1</sup>. Analyses of samples were carried out at 25 &#x000b1; 0.2 &#x000b0;C, 24 h, 3 months, and 6 months after preparation.</p></sec></sec><sec id="sec2dot4-pharmaceutics-17-00168"><title>2.4. Infrared Interaction Study</title><p>To obtain FTIR spectra of MD, CM, blank gel, and the emulgel formulation, a Thermo Scientific Nicolet iZ10, with an ATR diamond and DTGS detector, was used. The scanning range was 525&#x02013;4000 cm<sup>&#x02212;1</sup>.</p></sec><sec id="sec2dot5-pharmaceutics-17-00168"><title>2.5. In Vitro Drug Release</title><p>The drug release was investigated by vertical diffusion Franz cells (Microette Hanson Research<sup>&#x000ae;</sup>) at 32 &#x000b0;C with a diffusional area of 0.64 cm<sup>2</sup>, and a nylon membrane with 0.45 &#x000b5;m pore size was used. The receptor fluid was Milli-Q water/DMSO (80:20), which was continuously stirred at 324 rpm. A total of 250 mg of emulgel was applied to the membrane (n = 6), and aliquots of 300 &#x000b5;L were withdrawn at the sampling times: 0.16 h, 1 h, 3 h, 5.3 h, 8.1 h, 9.5 h, and 23.3 h. Following sample collection during the in vitro release tests, all samples were promptly stored at 4 &#x000b0;C in a refrigerator to maintain their stability and integrity. Sample analysis was performed immediately after completing the release test to ensure accurate and reliable quantification of the active ingredient. Samples were quantified separately by HPLC (High-Performance Liquid Chromatography).</p><p>The cumulative released amounts of each drug were plotted vs. time, and the kinetic profile of the drugs was determined by fitting the data to mathematical models and the goodness-of-fit was based on the best determination coefficient (<italic toggle="yes">r</italic><sup>2</sup>).</p></sec><sec id="sec2dot6-pharmaceutics-17-00168"><title>2.6. Ex Vivo Permeation</title><p>The permeability of the drugs was evaluated on human skin by vertical Franz diffusion cells. This study was carried out by the Hospital de Barcelona Ethics Committee (dated 17 January 2020); this study utilized human skin obtained from a healthy 38-year-old woman who underwent an abdominal lipectomy at Hospital de Barcelona, SCIAS, Barcelona, Spain, with prior written consent. The study was conducted as described in <xref rid="sec2dot5-pharmaceutics-17-00168" ref-type="sec">Section 2.5</xref> but using ex vivo human skin (n = 6) instead of the synthetic membrane. A total of 250 mg of emulgel was applied to the skin, and 300 &#x000b5;L were collected from the receptor medium at the sampling time points of 1 h, 5.5 h, 9.75 h, 23.4 h, 27.2 h, and 31.1 h and replaced with fresh receptor medium MiliQ water and DMSO (80:20). Receptor fluid samples were stored at 4 &#x000b0;C in a refrigerator immediately after collection to maintain stability until analysis. At the end of the assay, the drugs retained in the skin were extracted by adding 1 mL of solvent (water) to the skin and sonicated for 20 min. The supernatants were collected for further analysis. The samples of drug extraction from the skin were analysed immediately after collection, alongside the receptor fluid samples that had been kept in the refrigerator. Quantitative determination of the permeated MD and CM were analysed in triplicate by HPLC. Kinetic parameters were estimated using GraphPad Prism<sup>&#x000ae;</sup> 10.2.3) (GraphPad Software Inc., San Diego, CA, USA)<monospace>.</monospace></p><p>For the collected samples, the cumulative amount of MD and CM (&#x003bc;g) permeated per cm<sup>2</sup> of skin was plotted against time (h). The permeation profile was analysed based on the diffusion model for infinite dose conditions. The MD and CM flux through the skin ((<italic toggle="yes">J</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic>, g/(h)) was calculated by plotting the cumulative amount of drug permeated through the skin versus time, and the slope of the linear part of the curve was determined by linear regression analysis using GraphPad Prism<sup>&#x000ae;</sup> 10.2.3 divided by the diffusion area. The lag time (Tl, h) was determined as the X-intercept of the linear regression. The permeation coefficient (<italic toggle="yes">K</italic><italic toggle="yes">p</italic>, cm/h) was determined by dividing <italic toggle="yes">J</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic> by the initial drug concentration (<italic toggle="yes">Co</italic>, &#x000b5;g/mL) in the donor compartment. The partition and diffusion coefficients were estimated according to Equations (2) and (3):<disp-formula>P2 = 1/6 &#x000d7; Tl <label>(2)</label></disp-formula>
where Tl is the lag time previously determined as the X-intercept.<disp-formula>P1 = Kp/P2 <label>(3)</label></disp-formula>
where Kp is the permeability coefficient, and P2 is the partition coefficient.</p><p>The steady-state plasma concentration (Css) of the drug passing through the skin barrier after topical application was determined using the following Equation (4): <disp-formula><italic toggle="yes">C</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic> = <italic toggle="yes">J</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic> &#x000d7; <italic toggle="yes">A</italic>/<italic toggle="yes">Clp</italic>
<label>(4)</label></disp-formula>
where <italic toggle="yes">C</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic> is the steady-state plasma concentration, <italic toggle="yes">J</italic><italic toggle="yes">s</italic><italic toggle="yes">s</italic> is the flux, <italic toggle="yes">A</italic> is the area of application, and <italic toggle="yes">C</italic><italic toggle="yes">l</italic><italic toggle="yes">p</italic> the plasma clearance.</p></sec><sec id="sec2dot7-pharmaceutics-17-00168"><title>2.7. Analytical Method</title><p>The samples from the release and the permeation assays were analysed by HPLC (Alliance 2695 (A1.2) Waters) with a PDA detector (Waters 2996 (138C)). The column used was an ODS Hypersil<sup>&#x000ae;</sup> 250 &#x000d7; 4 mm, 5 &#x000b5;m Thermo. The analytical conditions for the determination of MD and CM are given in <xref rid="pharmaceutics-17-00168-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot8-pharmaceutics-17-00168"><title>2.8. Antibacterial Activity</title><sec id="sec2dot8dot1-pharmaceutics-17-00168"><title>2.8.1. Bacterial Strains and Culture Conditions</title><p>For this study, microorganisms present in the oily area of the skin, follicle, and sebaceous glands were selected. An <italic toggle="yes">Escherichia coli</italic> strain was also included as a model of Gram-negative bacillus. Strains were obtained from different culture collections: <italic toggle="yes">Staphylococcus epidermidis</italic> ATCC 12228, <italic toggle="yes">Staphylococcus aureus</italic> ATCC 29213, <italic toggle="yes">Micrococcus luteus</italic> ATCC 10240, <italic toggle="yes">Cutibacterium acnes</italic> ATCC 6919, <italic toggle="yes">Corynebacterium tuberculostearicum</italic> CECT 763 (ATCC 33035), <italic toggle="yes">Corynebacterium simulans</italic> DSM 44415, <italic toggle="yes">Staphylococcus capitis</italic> CECT 7101<sup>T</sup> (T = Type strain), <italic toggle="yes">Staphylococcus hominis</italic> CECT 234<sup>T</sup>, <italic toggle="yes">Streptococcus mitis</italic> DSM 12643, and <italic toggle="yes">Escherichia coli</italic> ATCC 25922.</p><p><italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. aureus, S. epidermidis</italic>, <italic toggle="yes">and M. luteus</italic> were incubated on Muller-Hinton (MH) agar at 37 &#x000b0;C in aerobic conditions. <italic toggle="yes">C. simulans, S. mitis, S. capitis</italic>, and <italic toggle="yes">S. hominis</italic> were incubated on agar plates prepared with Tryptic soy broth (TSB) + 0.3% yeast extract + 1.5% agar at 37 &#x000b0;C in aerobiosis. <italic toggle="yes">C. tuberculostearicum</italic> was incubated on agar plates with TSB + 0.1% tween 80 + 1.5% agar at 37 &#x000b0;C in aerobic conditions and <italic toggle="yes">C.acnes</italic> was incubated on MH agar plates at 37 &#x000b0;C in anaerobiosis. The same media have been used without agar for the microdilution method.</p></sec><sec id="sec2dot8dot2-pharmaceutics-17-00168"><title>2.8.2. Antimicrobials Interactions</title><p>Interactions between CM and MD have been determined by calculating the minimum inhibitory concentration (MIC) of each antibiotic separately and combinations of both. Assays were performed using the standardised broth microdilution method [<xref rid="B22-pharmaceutics-17-00168" ref-type="bibr">22</xref>]. Stock solutions of antibiotics were prepared in the broth culture indicated for each microorganism. For stock solutions, MD and DMSO were added, never exceeding 5% of the solvent. To study the interactions between the two antimicrobials, the microdilution plate was filled with 100 &#x000b5;L of doubly concentrated antibiotic. MD was distributed on the ordinate axis and CM was on the abscissa axis. Controls of the uninoculated culture medium, strain growth, and uninoculated antibiotic solutions were incorporated into the wells of the microdilution plates.</p><p>The strains used in the assay were incubated under optimal conditions, as mentioned in the previous section. Suspensions of 1 &#x000d7; 10<sup>8</sup> CFU/mL were prepared using a spectrophotometer (UV-1800 Simadzu UV Spectrophotometer) at 600 nm. The wells of the microdilution plate were inoculated with 10 &#x000b5;L of a 1/10 dilution of the microorganism suspension. At 48 h of incubation, a visual reading of the growth and a reading of the optical density was made by spectrophotometer (microplate Reader Synergy|HT, Biotek, Winooski, VT, USA).</p><p>Growth was calculated by determining the percentage growth of each of the antibiotic combinations concerning the positive control using the following equation:<disp-formula><italic toggle="yes">(ODp &#x02212; ODp C&#x02212;)/(OD C + OD C&#x02212;)</italic> &#x000d7; 100 <label>(5)</label></disp-formula></p><p><italic toggle="yes">ODp</italic> is the optical density of the well of one of the combinations of antibiotics; <italic toggle="yes">ODp C&#x02212;</italic> is the optical density of the same combination without inoculation; <italic toggle="yes">OD C+</italic> is the optical density of the positive growth control of that microorganism; and <italic toggle="yes">OD C&#x02212;</italic> is the optical density of the culture medium used without inoculation. Growth was considered to have occurred after a 10% increase for the positive control.</p></sec><sec id="sec2dot8dot3-pharmaceutics-17-00168"><title>2.8.3. Antimicrobial Efficacy</title><p>The antimicrobial activity of formulations was tested by using a modified disk diffusion test agar [<xref rid="B23-pharmaceutics-17-00168" ref-type="bibr">23</xref>], measuring the inhibition areas produced. The same microorganisms and culture conditions were used as described above, except for <italic toggle="yes">S. mitis</italic> due to the difficulty of surface growth, which has made it difficult to read the results.</p><p>Suspensions of the different microorganisms were prepared at a concentration of 0.5 on the McFarland scale. The strains were planted confluently in the appropriate medium with the aid of a soaked swab and rotating the plate at approximately 60 &#x000b0;C between each inoculation (three times) to ensure an even distribution of the inoculum. A total of 50 &#x000b5;L from the formulation with the two antimicrobials, as well as from the formulations with only MD, only CM, and without antimicrobials, was added. The same procedure was used for two solid commercial formulations: commercial formulation 1 (CO1) with 1% clindamycin and commercial formulation 2 (CO2) with 0.75% metronidazole. No more than three formulations per plate were placed and incubated under the optimal conditions for each microorganism described previously. Once the incubation time had elapsed, the inhibition halos were measured for each formulation and microorganism.</p></sec></sec><sec id="sec2dot9-pharmaceutics-17-00168"><title>2.9. Toxicity</title><p>Human keratinocytes (HaCaT) cells were cultured as described previously [<xref rid="B24-pharmaceutics-17-00168" ref-type="bibr">24</xref>]. Cells were grown in high glucose DMEM (Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (Thermofisher)), supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, 100 units/mL penicillin G, and 100 &#x000b5;g/mL streptomycin. Cells were incubated at 37 &#x000b0;C in an atmosphere of 5% CO2. For cytotoxicity assays, cells were grown at 80&#x02013;90% of confluence.</p><p>Cytotoxicities of MD and CM were determined by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, which measures the reduction of tetrazolium salt by intracellular dehydrogenases of viable living cells. Compounds were tested at concentrations indicated in the results section. For this, HaCaT cells were seeded in 96-well plates with 100 &#x003bc;L of culture medium (DMEM) at a density of 2 &#x000d7; 10<sup>4</sup> cells/well. When cells reached 90% confluency, cells were incubated with each compound or a mixture of both for 24 h. Then, the medium was removed and MTT (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) was added at 0.25% in PBS. After a 3 h incubation, the medium was replaced by 100 &#x000b5;L DMSO (99% dimethyl sulfoxide, Sigma-Aldrich). Cell viability was then determined at a wavelength of 570 nm in a Modulus<sup>&#x000ae;</sup> Microplate Photometer (Turner BioSystems Inc., Sunnyvale, CA, USA). Results were expressed as a percentage of cell survival relative to untreated cells. Since CM is not soluble in water, DMSO has been used as a solvent. For this reason, the cytotoxicity studies have included the analysis of the effect of DMSO present in the CM solutions after the corresponding dilutions.</p><p>The results were expressed as the percentage of cell survival relative to the control (untreated cells). See Equation (6).<disp-formula>Cell viability = ABS treated cells/ABS control cells &#x000d7; 100 <label>(6)</label></disp-formula></p></sec><sec id="sec2dot10-pharmaceutics-17-00168"><title>2.10. Inflammation Activity</title><p>The in vitro model of inflammation used in this study involved HACAT cells exposed to LPS-IFN&#x003b3; at 0.5 &#x000b5;g/mL and 0.02 &#x000b5;g/mL. Cells were incubated with MD and/or CM for 3 h before the addition of LPS-IFN&#x003b3;. In parallel, cells stimulated only with LPS-INF&#x003b3; were set as a positive control and untreated cells as a negative control [<xref rid="B25-pharmaceutics-17-00168" ref-type="bibr">25</xref>]. Following 48 h incubation, IL-6 secreted levels were quantified in the culture supernatant using the enzyme-linked immunosorbent assay (ELISA) (BD Biosciences, San Jose, CA, USA), according to the manufacturer&#x02019;s instructions. Data were representative of 3 independent experiments.</p></sec><sec id="sec2dot11-pharmaceutics-17-00168"><title>2.11. Data Analysis</title><p>The statistical analysis of the permeation studies was conducted using GraphPad Prism<sup>&#x000ae;</sup> 10.2.3 (GraphPad Software Inc., San Diego, CA, USA). The values were expressed as averages &#x000b1; SEM. The software packages Haake RheoWin<sup>&#x000ae;</sup>Job Manager V.3.3 and RheoWin<sup>&#x000ae;</sup>Data Manager V.3.3 (Thermo Electron Corporation, Karlsruhe, Germany) were used to carry out the testing and analysis of the obtained rheological data, respectively.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00168"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00168"><title>3.1. Characterization of the Emulgel</title><p>Once the emulgel was prepared, it showed a white colour, bright with uniform texture, lump-free, and no separate phase was detected. This was determined at time 0, 3, and 6 months after its preparation and did not show visual changes over time (<xref rid="pharmaceutics-17-00168-f002" ref-type="fig">Figure 2</xref>). Moreover, the morphology determination by microscopy of the MD-CM-gel showed dispersed and uniform particles over 6 months (<xref rid="pharmaceutics-17-00168-f003" ref-type="fig">Figure 3</xref>). The facial pH in rosacea patients is slightly acidic compared to the normal facial skin. So, the emulgel should have a pH between 5.5 and 6.5 (28). The pH was monitored at times 0, 3, and 6 months and no changes were observed during this period, the pH was stable, and the values are shown in <xref rid="pharmaceutics-17-00168-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot2-pharmaceutics-17-00168"><title>3.2. Extensibility</title><p><xref rid="pharmaceutics-17-00168-f004" ref-type="fig">Figure 4</xref> shows the extensibility of the MD-CM-gel as a function of weight. The extensibility was uniform and there were no changes over time. Statistical analysis showed significant differences between the initial time versus 3 and 6 months.</p></sec><sec id="sec3dot3-pharmaceutics-17-00168"><title>3.3. Droplet Size Determination</title><p>The droplet size of the MD-CM-gel was measured using the Mastersizer<sup>&#x000ae;</sup> 2000. <xref rid="pharmaceutics-17-00168-f005" ref-type="fig">Figure 5</xref> shows the distribution and uniform droplet for the emulgel over 6 months of its preparation, showing a particle size of approximately 3 &#x000b5;m. The measurement at 6 months showed a slight increase in the polydisperse index parameter.</p></sec><sec id="sec3dot4-pharmaceutics-17-00168"><title>3.4. Rheology</title><p>The steady shear properties of the MD-CM-gel are shown in <xref rid="pharmaceutics-17-00168-f006" ref-type="fig">Figure 6</xref>. Measurements showed that formulations displayed non-Newtonian behaviour. The formulations exhibited pseudoplastic flow and shear thinning behaviour since the viscosity decreased with an increase in the shear rate from 0.1 to 100 s<sup>&#x02212;1</sup>. <xref rid="pharmaceutics-17-00168-f006" ref-type="fig">Figure 6</xref> shows the rheograms for the MD-CM-gel freshly prepared, 3 months and 6 months. Although there was a decrease in the viscosity, the extensibility of the emulgel remained unchanged for 6 months, and the decrease in the viscosity had no relevant effect on the spreadability of the emulgel. As shown in <xref rid="pharmaceutics-17-00168-f006" ref-type="fig">Figure 6</xref>, viscosity values are 3052 &#x000b1; 23.59, 2879 &#x000b1; 48.56, and 2901 &#x000b1; 43.50 mPa.s for 0, 3, and 6 months, respectively (<xref rid="pharmaceutics-17-00168-t004" ref-type="table">Table 4</xref>). The thixotropic loop was formed between the ascending and descending curves and the area of the loop represented the energy required to break the system structure. The mathematical model that best fit the experimental data was the Cross equation, which describes a general model for pseudoplastic materials, Equation (7):
<disp-formula id="FD143567-pharmaceutics-17-00168"><label>(7)</label><mml:math id="mm156787" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">Cross</mml:mi><mml:mi mathvariant="italic">Equation</mml:mi><mml:mspace linebreak="newline"/><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003c4;</mml:mi><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x0221e;</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x0221e;</mml:mo></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mo>/</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#x003c4;</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> is the shear stress (Pa), <inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> is the shear rate (1/s), <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003b3;</mml:mi></mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula><sub>0</sub> is the zero shear rate (1/s), <inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the zero shear rate viscosity (Pa.s), <inline-formula><mml:math id="mm6" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x0221e;</mml:mo></mml:mrow></mml:msub><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula>is the infinity shear rate viscosity (Pa.s), <inline-formula><mml:math id="mm7" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> is the flow index.</p></sec><sec id="sec3dot5-pharmaceutics-17-00168"><title>3.5. Fourier Transform Infrared Spectroscopy</title><p>The FTIR analysis was conducted to study the interactions between the active ingredients and the excipients composing the emulgel. <xref rid="pharmaceutics-17-00168-f007" ref-type="fig">Figure 7</xref> depicts the spectra of the MD-CM-gel, the blank emulgel, and the pure drugs MD and CM.</p><p>CM (<xref rid="pharmaceutics-17-00168-f008" ref-type="fig">Figure 8</xref>a) is a very strong basic compound (based on its pKa) and MD (<xref rid="pharmaceutics-17-00168-f008" ref-type="fig">Figure 8</xref>b) is a weak base that appears to dissolve maximally at approximate pH &#x02264; 2.0; at high pH values, the drug has low solubility in water. Simulgel<sup>&#x000ae;</sup> 600 is composed of acrylamide/sodium acryloyldimethyltaurate copolymer, isohexadecane, and Polysorbate 80. According to the FTIR spectra, the -CONH carbonyl-amide group for CM is not significantly affected. However, the -OH groups of the MD are overlapped by the formulation. Therefore, no interactions with the active ingredients of this pharmaceutical formula occurred. Concerning the rest of the excipients of the emulgel, medium-chain triglycerides (MCTs) are a liquid oil manufactured through the esterification of glycerol using medium-chain fatty acids (caproic (6 C), caprylic (8 C); capric (10 C) and Lauric (12 C)) isolated from natural sources (coconut oil, palm oil, or a combination of the two). It contains carboxylic acids, which are weak acids esterified with glycerine that will not alter the activity of the active ingredients. They can help facilitate the solubility of these compounds. Isohexadecane, whose molecular formula is C16H34 and mass is 226.441 g/mol, is a saturated hydrocarbon with lipophilic properties. No interactions with the active ingredients of this pharmaceutical formula were observed either. Glycerine (<xref rid="pharmaceutics-17-00168-f008" ref-type="fig">Figure 8</xref>c) can establish hydrogen bond interactions with polar compounds that have hydroxyl groups or analogues.</p><p>Phenonip<sup>&#x000ae;</sup> is a mixture of phenoxyethanol (&#x02265;50%), methylparaben (10&#x02013;25%), propylparaben (5&#x02013;10%), and ethylparaben (1&#x02013;5%). It constitutes a broad bacteriostatic antimicrobial agent spectrum comprising a synergistic mixture of acid esters parahydroxybenzoic acid (parabens) in phenoxyethanol designed for the preservation of a wide range of cosmetics. Phenonip<sup>&#x000ae;</sup> presents antibacterial activity against Gram+ and Gram- bacteria, yeasts, and molds. No interactions with the active ingredients or excipients are expected.</p><p>Concerning possible interactions of the active substances with excipients, CM is a stable base that could form salts with carboxylic acids, but in this formulation, there are no acids to form salts. CM has three hydroxyl groups, which can form hydrogen bonds with water and/or glycerol, favouring solubility. These interactions do not affect the therapeutic activity or the analytical assays of clindamycin. The fatty acids of MCT are esterified with the glycerol that accompanies them. Concerning MD, which is a very weak base, no significant interactions with the excipients of the pharmaceutical formulation are expected.</p></sec><sec id="sec3dot6-pharmaceutics-17-00168"><title>3.6. In Vitro Drug Release Test</title><p><xref rid="pharmaceutics-17-00168-f009" ref-type="fig">Figure 9</xref> shows the release profile for CM and MD from the emulgel. The drugs are released in a sustained way up to nearly 24 h, with a faster release in the earlier times. Both drugs best fit the one-phase exponential association. <xref rid="pharmaceutics-17-00168-t005" ref-type="table">Table 5</xref> shows the parameter values for both drugs.</p></sec><sec id="sec3dot7-pharmaceutics-17-00168"><title>3.7. Ex Vivo Permeation Test</title><p>The permeation study was conducted on ex vivo human skin under an infinite-dose approach. The permeation profiles of the drugs through human skin are depicted in <xref rid="pharmaceutics-17-00168-f010" ref-type="fig">Figure 10</xref>. The permeation parameters for both drugs are shown in <xref rid="pharmaceutics-17-00168-t006" ref-type="table">Table 6</xref>.</p><p>CM presents a 10-fold flux related to MD. Nevertheless, the lag time for CM is nearly twice the one for MD, resulting in a higher permeability coefficient (<italic toggle="yes">Kp</italic>) for CM. In both drugs, the parameter P2 is higher than P1 indicating that the driving force of the permeation is mainly influenced by the diffusion capacity of the drugs in permeating the skin rather than the partition coefficient vehicle-skin; this fact is especially remarkable for MD, as P2 is about 50-fold higher than P1. Concerning the drug amount retained in the skin, MD is more retained than CM.</p></sec><sec id="sec3dot8-pharmaceutics-17-00168"><title>3.8. Results for Antimicrobial Activity</title><sec id="sec3dot8dot1-pharmaceutics-17-00168"><title>3.8.1. Interaction Between Antimicrobials</title><p>CM showed a lower MIC compared to MD (<xref rid="pharmaceutics-17-00168-t007" ref-type="table">Table 7</xref>). When the two antimicrobials were combined, the MIC decreased by at least one dilution for both MD and CM compared to their MIC separately. This decrease in MIC occurred for all the strains studied.</p></sec><sec id="sec3dot8dot2-pharmaceutics-17-00168"><title>3.8.2. Antimicrobial Activity of the Formulation</title><p>The two formulations, MD-CM-gel and CM-gel with clindamycin alone, show clear antimicrobial activity with similar or slightly higher areas of inhibition in the combination of the two products (<xref rid="pharmaceutics-17-00168-t008" ref-type="table">Table 8</xref>). On the other hand, the formulation with only MD, MD-gel, has little or no activity on the microorganisms studied, but when combined with CM, it does not interfere or else facilitate a slight increase in the area of inhibition. The formulation without antibiotic, white gel, does not produce any type of inhibition on the microorganisms studied, as can be seen in <xref rid="pharmaceutics-17-00168-f011" ref-type="fig">Figure 11</xref>.</p><p><xref rid="pharmaceutics-17-00168-t009" ref-type="table">Table 9</xref> shows the inhibition halos originated by the solid commercial formulations. The CO1 formulation with clindamycin has activity on the strains studied, but the areas of inhibition are somewhat lower than those of our formulation with the two antimicrobials. However, the solid formulation with only MD inhibits little or no growth in strains (<xref rid="pharmaceutics-17-00168-f012" ref-type="fig">Figure 12</xref>).</p></sec></sec><sec id="sec3dot9-pharmaceutics-17-00168"><title>3.9. Toxicity Assay</title><p>The cytotoxicity of MD and CM was evaluated on HaCaT cells after a 24 h incubation at the concentrations indicated in <xref rid="pharmaceutics-17-00168-f013" ref-type="fig">Figure 13</xref>A. Results showed that MD was not cytotoxic at concentrations ranging from 1.5 to 6 &#x000b5;g/mL, as cell viability was kept close to the untreated control cells. In contrast, CM caused a significant cytotoxic effect at the higher concentration tested (0.8 &#x000b5;g/mL). At this concentration, cell viability was 10% compared to untreated control cells. At the lowest dose (0.2 &#x000b5;g/mL), cell viability was approximately 100%. In this scenario, we decided to analyse whether the presence of MD could potentiate CM cytotoxicity. For this study, we established experimental conditions to select the MD dose at 3 &#x000b5;g/mL and CM at increasing concentrations. The MTT assay revealed that MD, at the concentration used, did not exert any effect on CM cytotoxicity since cell viability, after 24 h incubation, remained close to that observed with CM alone, at the same concentrations (<xref rid="pharmaceutics-17-00168-f013" ref-type="fig">Figure 13</xref>B).</p></sec><sec id="sec3dot10-pharmaceutics-17-00168"><title>3.10. Inflammation Model and Quantification of IL-6 by ELISA</title><p>Since MD has anti-inflammatory effects at the topic levels and CM is an antibiotic used to treat certain bacterial infections affecting the skin, it was decided to analyse if CM could influence the anti-inflammatory effects of MD. Taking into consideration the cytotoxicity results, this analysis was performed with CM (0.2 &#x000b5;g/mL) and MD (0.3 &#x000b5;g/mL) using the in vitro LPS-IFN&#x003b3; model of inflammation. Inflammation was evaluated by determining the IL-6 secreted levels by ELISA (<xref rid="pharmaceutics-17-00168-f014" ref-type="fig">Figure 14</xref>). The results showed that MD at 0.3 &#x000b5;g/mL significantly reduced, by more than 50%, the IL-6 levels induced by LPS-IFN&#x003b3;, and CM at 0.2 &#x000b5;g/mL did not significantly interfere with its anti-inflammatory effect.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00168"><title>4. Discussion</title><p>Rosacea is a chronic inflammatory skin condition characterised by facial redness, papules, and pustules. Topical treatments are often preferred due to their localised action and reduced systemic side effects. There are various topical formulations containing MD or CM used to treat rosacea [<xref rid="B26-pharmaceutics-17-00168" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00168" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00168" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00168" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00168" ref-type="bibr">30</xref>]. However, to our knowledge, there is no specific mention of a combined topical formulation containing both MD and CM for this condition. However, both agents are individually effective in treating rosacea, with MD being well-studied and commonly used. Based on the benefits of combined therapies combining MD and oral antibiotics [<xref rid="B14-pharmaceutics-17-00168" ref-type="bibr">14</xref>,<xref rid="B31-pharmaceutics-17-00168" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00168" ref-type="bibr">32</xref>], a topical formulation combining MD and CM was developed. The excipient selection of the emulgel formulations was based on non-comedogenic nor occlusive properties since the skin in rosacea patients is generally sensitive and intolerant [<xref rid="B33-pharmaceutics-17-00168" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00168" ref-type="bibr">34</xref>]. Glycerine provides smoothness and has moisturising and lubricant properties. The oily phase consisted of four ingredients combined in Simulgel<sup>&#x000ae;</sup> 600, which is an emulsifying base with excellent skin tolerability. The addition of water leads to the formation of a stable polymeric network that retains the oily components within its structure. The medium-chain triglycerides exert an emollient action and provide good extensibility of the emulgel [<xref rid="B35-pharmaceutics-17-00168" ref-type="bibr">35</xref>]. Isohexadecane also acts as an emollient and skin conditioner. The formulation contains Phenonip<sup>&#x000ae;</sup> to prevent fungal and bacterial contamination. Silicone emulsions (W/S), which do not contain lipids, are also considered good alternatives to the marketed products for the treatment of rosacea [<xref rid="B36-pharmaceutics-17-00168" ref-type="bibr">36</xref>].</p><p>In this study, the MD-CM-gel demonstrated ideal organoleptic properties for dermal application, offering excellent homogeneity, particle size, and consistency, with a pleasant texture and ease of use. The pH values remained stable at 5.7, 5.8, and 5.7 over 6 months, confirming the formulation&#x02019;s biocompatibility with the skin and ensuring it would not cause irritation. Rheological analysis revealed valuable insights regarding the ease of application, sensory characteristics, and dispensing properties, while also influencing biopharmaceutical factors like drug release rates. The MD-CM-gel displayed a pseudoplastic behaviour with an average viscosity of 2944 &#x000b1; 38.55 mPa.s at 25 &#x000b0;C [<xref rid="B37-pharmaceutics-17-00168" ref-type="bibr">37</xref>].</p><p>FTIR analysis was performed to identify the interactions between MD-CM-gel, the blank emulgel, and the pure drugs MD and CM. According to the analysis of the spectra of each formulation (<xref rid="pharmaceutics-17-00168-f007" ref-type="fig">Figure 7</xref>), there was no evidence of the existence of a covalent bond between the elements that constituted the emulgel. These results are what can be expected in line with those set forth by other authors [<xref rid="B38-pharmaceutics-17-00168" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-00168" ref-type="bibr">39</xref>]. In vitro drug release studies are conducted to investigate how the drugs are released from the formulation and are available to the skin. The tests allow us to refine and optimize the formulations. The study revealed that CM was released in a significantly lower amount compared to MD. This could be indicative of the different molecular interactions within the emulgel matrix [<xref rid="B40-pharmaceutics-17-00168" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-00168" ref-type="bibr">41</xref>]. MD exhibits higher water solubility (5.92 mg/mL) compared to CM (3.1 mg/mL) [<xref rid="B42-pharmaceutics-17-00168" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00168" ref-type="bibr">43</xref>], facilitating faster diffusion from the emulgel matrix into the aqueous release medium [<xref rid="B44-pharmaceutics-17-00168" ref-type="bibr">44</xref>]. MD&#x02019;s pKa values (2.57 and 15.42) promote ionization at pH~7, enhancing its aqueous solubility and contributing to faster release, while CM, with a pKa of 7.6, is less ionized [<xref rid="B45-pharmaceutics-17-00168" ref-type="bibr">45</xref>]. Additionally, smaller molecules, like MD (molecular weight 171.96 g/mol), diffuse more easily, leading to faster release, whereas larger molecules, like CM (molecular weight 424.98 g/mol), face more resistance [<xref rid="B46-pharmaceutics-17-00168" ref-type="bibr">46</xref>]. Lipophilicity also impacts release [<xref rid="B47-pharmaceutics-17-00168" ref-type="bibr">47</xref>]; MD, being more hydrophilic (log P = &#x02212;0.02), is more water-soluble and releases faster, whereas CM, being more lipophilic (log P = 2.16), tends to interact more with lipid components, slowing its release. These physicochemical properties explain the differences in the release profiles of MD and CM from the emulgel.</p><p>A lower release of CM does not imply therapeutic failure, as long as enough of the drug reaches the target. The slower release may even be beneficial, reducing systemic absorption and minimising the risk of adverse effects like antibiotic resistance or toxicity. In contrast, the faster release of MD supports its anti-inflammatory role, offering more immediate symptom relief. The complementary release profiles of CM and MD work synergistically, addressing both microbial and inflammatory aspects of rosacea effectively. Microbiological studies also showed synergy between CM and MD, with a significant reduction in minimum inhibitory concentration (MIC) and larger inhibition halos compared to individual drugs. These findings suggest the combined formulation may enhance efficacy against rosacea-associated microorganisms. However, further preclinical and clinical studies are needed to confirm these benefits and understand the combination&#x02019;s full potential in clinical practice.</p><p>The mathematical modelling of these release profiles enables us to describe the behaviour of these drugs during the release process. The one-phase association kinetic model best described the release of the drugs, suggesting a rapid initial release followed by a plateau, a pattern often desired in topical applications for sustained effect [<xref rid="B24-pharmaceutics-17-00168" ref-type="bibr">24</xref>]. Despite the lower release amount of CM, the release rate was only slightly slower than MD.</p><p>Ex vivo permeation tests are conducted using human or animal skin and provide insights into the absorption, penetration, and retention of topical formulations, which is valuable in the development of effective dermatological treatments. By understanding how active ingredients behave, researchers can optimise drug delivery systems and ensure safety and efficacy before clinical trials. This approach not only accelerates the research and development process but also reduces the reliance on animal testing, aligning with the ethical standards of modern pharmacology [<xref rid="B48-pharmaceutics-17-00168" ref-type="bibr">48</xref>]. In our study, we observed a greater flux for CM compared to MD, which is 6.5-fold higher, suggesting that CM has a more efficient transdermal transport rate. This is further supported by the permeability coefficient (<italic toggle="yes">kp</italic>) being approximately three times higher for CM, indicating a more pronounced tendency for CM to penetrate the skin barrier. However, the lag time for CM is twice that of MD, which implies that, while CM permeates more effectively once initiated, its onset is slower. This could be attributed to the physicochemical properties of CM. Physicochemical properties, such as lipophilicity, melting point, molecular weight, Log P, and solubility of the drugs, impact the permeation capacity [<xref rid="B49-pharmaceutics-17-00168" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-00168" ref-type="bibr">50</xref>]. The stark contrast of <italic toggle="yes">P1</italic> between DM and MD indicates that CM presents higher affinity. <italic toggle="yes">Elewski</italic> investigated the percutaneous absorption of MD in different vehicles and concentrations. The study found that the vehicle significantly affects the percutaneous absorption of the MD and cream formulations showed the highest penetration, followed by lotions and gels [<xref rid="B51-pharmaceutics-17-00168" ref-type="bibr">51</xref>].</p><p>In both cases, the diffusion coefficient (<italic toggle="yes">P</italic>2) was greater than <italic toggle="yes">P</italic>1, especially for MD, indicating that the driving force behind the permeation is mainly due to the physicochemical properties of the drugs. The similar <italic toggle="yes">P</italic>2 values for both drugs indicate that their molecular mobility within the skin is comparable. Yet, the difference in the amount retained in the skin points to a greater affinity of MD for the skin tissue than for the receptor fluid, which could explain the higher retention of MD in the skin despite its lower permeation. This suggests that MD may be more localized in the skin, potentially leading to a local therapeutic effect but less systemic absorption. The potential local effect is supported by the predicted plasma concentration that would be achieved at the steady state after the application of the emulgel to the skin: the estimated <italic toggle="yes">Css</italic> for both drugs would be much below those plasma concentrations observed in the oral route of administration suggesting that the application of the emulgel via the cutaneous route would not cause systemic side effects, hence, the emulgel would be a safe dosage form [<xref rid="B52-pharmaceutics-17-00168" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00168" ref-type="bibr">53</xref>].</p><p>Microbiological assays have established that the combination of CM and MD does not counteract each other but even enhances the antimicrobial activity of CM. From a microbiological point of view, the efficacy of the formulation is superior to commercial formulations with CM alone or MD alone. Since there is an overgrowth of certain microorganisms in skin with rosacea and inflammatory processes [<xref rid="B54-pharmaceutics-17-00168" ref-type="bibr">54</xref>], the formulation with MD and CM can help in both processes. CM can reduce the overgrowth of microorganisms found on the skin and MD can reduce inflammation, as seen in other studies [<xref rid="B55-pharmaceutics-17-00168" ref-type="bibr">55</xref>]. This combination of effects explains the reduction in symptoms of the formulation. The combination of the two active ingredients facilitates the application of the treatment for rosacea disease.</p><p>Moreover, the HaCaT cell line is commonly used for in vitro toxicity assessment of dermal formulations before pre-clinical testing on animal models. This is due to their ease of cultivation, rapid growth, and high sensitivity to toxic agents, similar to other cell lines [<xref rid="B56-pharmaceutics-17-00168" ref-type="bibr">56</xref>]. In this study, the results confirmed that MD was not cytotoxic at concentrations ranging from 1.5 to 6.0 &#x000b5;g/mL, and CM at 0.2 &#x000b5;g/mL did not induce significant cytotoxic effects on HaCaT cells, demonstrating their good biocompatibility with human keratinocytes [<xref rid="B57-pharmaceutics-17-00168" ref-type="bibr">57</xref>].</p><p>Cytokines are regulatory proteins that play a key role in inflammatory responses [<xref rid="B58-pharmaceutics-17-00168" ref-type="bibr">58</xref>]. Interleukin-6 (IL-6) is a significant pro-inflammatory cytokine involved in the pathogenesis of rosacea. Elevated levels of IL-6 have been observed in patients with rosacea, indicating its role in the inflammatory processes associated with the condition [<xref rid="B59-pharmaceutics-17-00168" ref-type="bibr">59</xref>]. IL-6 contributes to the immune response, inflammation, and angiogenesis, which are key factors in the development and severity of rosacea [<xref rid="B60-pharmaceutics-17-00168" ref-type="bibr">60</xref>]. Inflammation was evaluated by measuring IL-6 secretion levels using ELISA (<xref rid="pharmaceutics-17-00168-f014" ref-type="fig">Figure 14</xref>). The findings revealed that MD at 0.3 &#x000b5;g/mL significantly reduced IL-6 levels induced by LPS-IFN&#x003b3; by over 50%. In contrast, CM at 0.2 &#x000b5;g/mL did not significantly alter its anti-inflammatory effect [<xref rid="B61-pharmaceutics-17-00168" ref-type="bibr">61</xref>]. Metronidazole&#x02019;s ability to modulate IL-6 in rosacea is likely due to its broader anti-inflammatory and antimicrobial properties. In rosacea patients, the increased levels of IL-6 correlate with ROS production and activation of the hypoxia-induced factor HIF-1&#x003b1; [<xref rid="B59-pharmaceutics-17-00168" ref-type="bibr">59</xref>,<xref rid="B62-pharmaceutics-17-00168" ref-type="bibr">62</xref>], and both effects are mediated through the IL-6/JAK/STAT3 pathway [<xref rid="B63-pharmaceutics-17-00168" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-00168" ref-type="bibr">64</xref>]. By reducing IL-6 levels, metronidazole may contribute to a decrease in the oxidative stress response and the associated symptoms of rosacea.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00168"><title>5. Conclusions</title><p>The development of an emulgel formulation combining MD and CM showed promising results as a possible treatment for rosacea. The formulation exhibited appropriate physicochemical and biopharmaceutical properties and sustained drug release. Additionally, it demonstrated adequate permeability through human skin and showed no toxicity in a HaCaT cell model. Antimicrobial studies revealed that the combination of MD and CM does not exhibit antagonism and is more effective than commercial treatments or antibiotics used separately. MD-CM-gel is effective against the most frequent bacterial strains found on the human sebaceous skin. Moreover, the MD and CM did not induce significant cytotoxic effects on HaCaT cells and the efficacy assessment, based on IL-6 secretion levels, demonstrated that MD significantly reduced IL-6 levels induced by LPS-IFN&#x003b3; by more than 50%.</p><p>The properties of the dual-active emulgel formulation represent an advance in the prevention and treatment of rosacea and may facilitate compliance in patients with this skin condition, as only a single application would be required. These results suggest that MD-CM emulgel may be an effective alternative for the treatment of rosacea, pending further preclinical and clinical studies.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Maria Jes&#x000fa;s Montes, Josefa Badia Palacin, Laura Baldoma, and Ana Pons for their scientific support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>G.D.G.-B. carried out the investigation; A.C.C.-C. carried out the supervision/resources and project administration; M.S.-A. writing&#x02014;review and editing the manuscript; J.S.-C. writing&#x02014;original draft and investigational; M.M.-M. analysed the formal analysis and visualization; S.M.-R. and C.C. carried out the investigational and data analysis; A.D.P. carried out the project administration and N.B.-d.F. carried out the supervision and data curation. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The use of human skin for the ex vivo permeation study was approved by the Bioethics Committee of the Barcelona-SCIAS Hospital (protocol N&#x000ba;002, dated 17 January 2020).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00168"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dall&#x02019;Oglio</surname><given-names>F.</given-names></name>
<name><surname>Nasca</surname><given-names>M.R.</given-names></name>
<name><surname>Micali</surname><given-names>G.</given-names></name>
</person-group><article-title>Emerging Topical Drugs for the Treatment of Rosacea</article-title><source>Expert. Opin. Emerg. Drugs</source><year>2021</year><volume>26</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/14728214.2021.1887138</pub-id><pub-id pub-id-type="pmid">33596752</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00168"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Zuuren</surname><given-names>E.J.</given-names></name>
<name><surname>Arents</surname><given-names>B.W.M.</given-names></name>
<name><surname>van der Linden</surname><given-names>M.M.D.</given-names></name>
<name><surname>Vermeulen</surname><given-names>S.</given-names></name>
<name><surname>Fedorowicz</surname><given-names>Z.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
</person-group><article-title>Rosacea: New Concepts in Classification and Treatment</article-title><source>Am. J. Clin. Dermatol.</source><year>2021</year><volume>22</volume><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1007/s40257-021-00595-7</pub-id><pub-id pub-id-type="pmid">33759078</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00168"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woo</surname><given-names>Y.R.</given-names></name>
<name><surname>Han</surname><given-names>Y.J.</given-names></name>
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
<name><surname>Cho</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Updates on the Risk of Neuropsychiatric and Gastrointestinal Comorbidities in Rosacea and Its Possible Relationship with the Gut&#x02013;Brain&#x02013;Skin Axis</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8427</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21228427</pub-id><pub-id pub-id-type="pmid">33182618</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00168"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>M.V.</given-names></name>
<name><surname>Jarratt</surname><given-names>M.</given-names></name>
<name><surname>Kaplan</surname><given-names>D.</given-names></name>
<name><surname>Tuley</surname><given-names>M.R.</given-names></name>
<name><surname>Baker</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Once-Daily Topical Metronidazole Cream Formulations in the Treatment of the Papules and Pustules of Rosacea</article-title><source>J. Am. Acad. Dermatol.</source><year>2001</year><volume>45</volume><fpage>723</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1067/mjd.2001.116219</pub-id><pub-id pub-id-type="pmid">11606923</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00168"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Two</surname><given-names>A.M.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Gallo</surname><given-names>R.L.</given-names></name>
<name><surname>Hata</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Rosacea: Part I. Introduction, Categorization, Histology, Pathogenesis, and Risk Factors</article-title><source>J. Am. Acad. Dermatol.</source><year>2015</year><volume>72</volume><fpage>749</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2014.08.028</pub-id><pub-id pub-id-type="pmid">25890455</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00168"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilkin</surname><given-names>J.</given-names></name>
<name><surname>Dahl</surname><given-names>M.</given-names></name>
<name><surname>Detmar</surname><given-names>M.</given-names></name>
<name><surname>Drake</surname><given-names>L.</given-names></name>
<name><surname>Feinstein</surname><given-names>A.</given-names></name>
<name><surname>Odom</surname><given-names>R.</given-names></name>
<name><surname>Powell</surname><given-names>F.</given-names></name>
</person-group><article-title>Standard Classification of Rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea</article-title><source>J. Am. Acad. Dermatol.</source><year>2002</year><volume>46</volume><fpage>584</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1067/mjd.2002.120625</pub-id><pub-id pub-id-type="pmid">11907512</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00168"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuller</surname><given-names>D.</given-names></name>
<name><surname>Martin</surname><given-names>S.</given-names></name>
</person-group><article-title>Rosacea</article-title><source>J. Midwifery Womens Health</source><year>2012</year><volume>57</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1111/j.1542-2011.2011.00156.x</pub-id><pub-id pub-id-type="pmid">22727268</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00168"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarmuda</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Reilly</surname><given-names>N.</given-names></name>
<name><surname>Zaba</surname><given-names>R.</given-names></name>
<name><surname>Jakubowicz</surname><given-names>O.</given-names></name>
<name><surname>Szkaradkiewicz</surname><given-names>A.</given-names></name>
<name><surname>Kavanagh</surname><given-names>K.</given-names></name>
</person-group><article-title>Potential Role of Demodex Mites and Bacteria in the Induction of Rosacea</article-title><source>J. Med. Microbiol.</source><year>2012</year><volume>61</volume><fpage>1504</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.048090-0</pub-id><pub-id pub-id-type="pmid">22933353</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00168"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Potential Role of Microorganisms in the Pathogenesis of Rosacea</article-title><source>J. Am. Acad. Dermatol.</source><year>2013</year><volume>69</volume><fpage>1025</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2013.08.006</pub-id><pub-id pub-id-type="pmid">24011460</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00168"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daou</surname><given-names>H.</given-names></name>
<name><surname>Paradiso</surname><given-names>M.</given-names></name>
<name><surname>Hennessy</surname><given-names>K.</given-names></name>
<name><surname>Seminario-Vidal</surname><given-names>L.</given-names></name>
</person-group><article-title>Rosacea and the Microbiome: A Systematic Review</article-title><source>Dermatol. Ther.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s13555-020-00460-1</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-00168"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barco</surname><given-names>D.</given-names></name>
<name><surname>Alomar</surname><given-names>A.</given-names></name>
</person-group><article-title>Rosacea</article-title><source>Actas Dermo-Sifiliogr&#x000e1;ficas (Engl. Ed.)</source><year>2008</year><volume>99</volume><fpage>244</fpage><lpage>256</lpage></element-citation></ref><ref id="B12-pharmaceutics-17-00168"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Culp</surname><given-names>B.</given-names></name>
<name><surname>Scheinfeld</surname><given-names>N.</given-names></name>
</person-group><article-title>Rosacea: A Review</article-title><source>Pharm. Ther.</source><year>2009</year><volume>34</volume><fpage>38</fpage></element-citation></ref><ref id="B13-pharmaceutics-17-00168"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceruelos</surname><given-names>A.H.</given-names></name>
<name><surname>Romero-Quezada</surname><given-names>L.C.</given-names></name>
<name><surname>Ledezma</surname><given-names>J.C.R.</given-names></name>
<name><surname>Contreras</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Therapeutic Uses of Metronidazole and Its Side Effects: An Update</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2019</year><volume>23</volume><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">30657582</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00168"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClellan</surname><given-names>K.J.</given-names></name>
<name><surname>Noble</surname><given-names>S.</given-names></name>
</person-group><article-title>Topical Metronidazole</article-title><source>Am. J. Clin. Dermatol.</source><year>2000</year><volume>1</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.2165/00128071-200001030-00007</pub-id><pub-id pub-id-type="pmid">11702300</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00168"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abokwidir</surname><given-names>M.</given-names></name>
<name><surname>Feldman</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Rosacea Management</article-title><source>Skin. Appendage Disord.</source><year>2016</year><volume>2</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1159/000446215</pub-id><pub-id pub-id-type="pmid">27843919</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00168"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Kroumpouzos</surname><given-names>G.</given-names></name>
<name><surname>Kassir</surname><given-names>M.</given-names></name>
<name><surname>Galadari</surname><given-names>H.</given-names></name>
<name><surname>Goren</surname><given-names>A.</given-names></name>
<name><surname>Grabbe</surname><given-names>S.</given-names></name>
<name><surname>Goldust</surname><given-names>M.</given-names></name>
</person-group><article-title>Rosacea Management: A Comprehensive Review</article-title><source>J. Cosmet. Dermatol.</source><year>2022</year><volume>21</volume><fpage>1895</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1111/jocd.14816</pub-id><pub-id pub-id-type="pmid">35104917</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00168"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>T.</given-names></name>
<name><surname>Waisman</surname><given-names>M.</given-names></name>
</person-group><article-title>Topically Administered Clindamycin in the Treatment of Acne Vulgaris and Other Dermatologic Disorders</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>1981</year><volume>1</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.1981.tb02541.x</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-00168"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilkin</surname><given-names>J.K.</given-names></name>
<name><surname>DeWITT</surname><given-names>S.U.E.L.L.E.N.</given-names></name>
</person-group><article-title>Treatment of rosacea: Topical clindamycin versus oral tetracycline</article-title><source>Int. J. Dermatol.</source><year>1993</year><volume>32</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4362.1993.tb00974.x</pub-id><pub-id pub-id-type="pmid">8425809</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00168"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garg</surname><given-names>T.</given-names></name>
<name><surname>Rath</surname><given-names>G.</given-names></name>
<name><surname>Goyal</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Comprehensive Review on Additives of Topical Dosage Forms for Drug Delivery</article-title><source>Drug Deliv.</source><year>2015</year><volume>22</volume><fpage>969</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.3109/10717544.2013.879355</pub-id><pub-id pub-id-type="pmid">24456019</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00168"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Talat</surname><given-names>M.</given-names></name>
<name><surname>Zaman</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>R.</given-names></name>
<name><surname>Jamshaid</surname><given-names>M.</given-names></name>
<name><surname>Akhtar</surname><given-names>M.</given-names></name>
<name><surname>Mirza</surname><given-names>A.Z.</given-names></name>
</person-group><article-title>Emulgel: An Effective Drug Delivery System</article-title><source>Drug Dev. Ind. Pharm.</source><year>2021</year><volume>47</volume><fpage>1193</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1080/03639045.2021.1993889</pub-id><pub-id pub-id-type="pmid">34647512</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00168"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amgaonkar</surname><given-names>Y.</given-names></name>
<name><surname>Kochar</surname><given-names>N.</given-names></name>
<name><surname>Chandewar</surname><given-names>A.</given-names></name>
<name><surname>Bute</surname><given-names>S.</given-names></name>
<name><surname>Wadher</surname><given-names>K.</given-names></name>
<name><surname>Umekar</surname><given-names>M.</given-names></name>
</person-group><article-title>Overview of Emulgel as Emergent Topical Delivery: Recent Applications and Advancement</article-title><source>J. Pharm. Res. Int.</source><year>2021</year><volume>33</volume><fpage>258</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.9734/jpri/2021/v33i62B35565</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-00168"><label>22.</label><element-citation publication-type="journal"><article-title>Determination of Minimum Inhibitory Concentrations (MICs) of Antibacterial Agents by Broth Dilution</article-title><source>Clin. Microbiol. Infect.</source><year>2003</year><volume>9</volume><fpage>ix</fpage><lpage>xv</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2003.00790.x</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00168"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>A.W.</given-names></name>
<name><surname>Kirby</surname><given-names>W.M.M.</given-names></name>
<name><surname>Sherris</surname><given-names>J.C.</given-names></name>
<name><surname>Turck</surname><given-names>M.</given-names></name>
</person-group><article-title>Antibiotic Susceptibility Testing by a Standardized Single Disk Method</article-title><source>Am. J. Clin. Pathol.</source><year>1966</year><volume>45</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1093/ajcp/45.4_ts.493</pub-id><pub-id pub-id-type="pmid">5325707</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00168"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva-Abreu</surname><given-names>M.</given-names></name>
<name><surname>Sosa</surname><given-names>L.</given-names></name>
<name><surname>Espinoza</surname><given-names>L.C.</given-names></name>
<name><surname>F&#x000e1;brega</surname><given-names>M.-J.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Lagunas</surname><given-names>M.J.</given-names></name>
<name><surname>Mallandrich</surname><given-names>M.</given-names></name>
<name><surname>Calpena</surname><given-names>A.C.</given-names></name>
<name><surname>Gardu&#x000f1;o-Ram&#x000ed;rez</surname><given-names>M.L.</given-names></name>
<name><surname>Rinc&#x000f3;n</surname><given-names>M.</given-names></name>
</person-group><article-title>Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2403</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15102403</pub-id><pub-id pub-id-type="pmid">37896163</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00168"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Folle</surname><given-names>C.</given-names></name>
<name><surname>Marqu&#x000e9;s</surname><given-names>A.M.</given-names></name>
<name><surname>D&#x000ed;az-Garrido</surname><given-names>N.</given-names></name>
<name><surname>Espina</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e1;nchez-L&#x000f3;pez</surname><given-names>E.</given-names></name>
<name><surname>Badia</surname><given-names>J.</given-names></name>
<name><surname>Baldoma</surname><given-names>L.</given-names></name>
<name><surname>Calpena</surname><given-names>A.C.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Thymol-Loaded PLGA Nanoparticles: An Efficient Approach for Acne Treatment</article-title><source>J. Nanobiotechnology</source><year>2021</year><volume>19</volume><fpage>359</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-01092-z</pub-id><pub-id pub-id-type="pmid">34749747</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00168"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monk</surname><given-names>B.E.</given-names></name>
<name><surname>Logan</surname><given-names>R.A.</given-names></name>
<name><surname>Cook</surname><given-names>J.</given-names></name>
<name><surname>White</surname><given-names>J.E.</given-names></name>
<name><surname>Mason</surname><given-names>R.B.S.</given-names></name>
</person-group><article-title>Topical Metronidazole in the Treatment of Rosacea</article-title><source>J. Dermatol. Treat.</source><year>1991</year><volume>2</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.3109/09546639109092728</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-00168"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinde</surname><given-names>U.A.</given-names></name>
<name><surname>Parmar</surname><given-names>S.J.</given-names></name>
<name><surname>Easwaran</surname><given-names>S.</given-names></name>
</person-group><article-title>Metronidazole-Loaded Nanostructured Lipid Carriers to Improve Skin Deposition and Retention in the Treatment of Rosacea</article-title><source>Drug Dev. Ind. Pharm.</source><year>2019</year><volume>45</volume><fpage>1039</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1080/03639045.2019.1569026</pub-id><pub-id pub-id-type="pmid">30727789</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00168"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Lei</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Tan</surname><given-names>F.</given-names></name>
</person-group><article-title>In Vitro/in Vivo Characterization of Nanoemulsion Formulation of Metronidazole with Improved Skin Targeting and Anti-Rosacea Properties</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2014</year><volume>88</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.03.019</pub-id><pub-id pub-id-type="pmid">24704200</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00168"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>S.A.</given-names></name>
<name><surname>Moon</surname><given-names>S.D.</given-names></name>
<name><surname>Spencer</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel for Rosacea: Summary of a Placebo-Controlled, Double-Blind Trial</article-title><source>J. Drugs Dermatol.</source><year>2012</year><volume>11</volume><fpage>1410</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">23377509</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00168"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fatima</surname><given-names>N.</given-names></name>
<name><surname>Rehman</surname><given-names>S.</given-names></name>
<name><surname>Nabi</surname><given-names>B.</given-names></name>
<name><surname>Baboota</surname><given-names>S.</given-names></name>
<name><surname>Ali</surname><given-names>J.</given-names></name>
</person-group><article-title>Harnessing Nanotechnology for Enhanced Topical Delivery of Clindamycin Phosphate</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2019</year><volume>54</volume><fpage>101253</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101253</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00168"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fowler</surname><given-names>J.F.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Combined Effect of Anti-Inflammatory Dose Doxycycline (40-Mg Doxycycline, Usp Monohydrate Controlled-Release Capsules) and Metronidazole Topical Gel 1% in the Treatment of Rosacea</article-title><source>J. Drugs Dermatol.</source><year>2007</year><volume>6</volume><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">17668530</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00168"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Conde</surname><given-names>J.F.</given-names></name>
<name><surname>Yelverton</surname><given-names>C.B.</given-names></name>
<name><surname>Balkrishnan</surname><given-names>R.</given-names></name>
<name><surname>Fleischer</surname><given-names>A.B.</given-names><suffix>Jr.</suffix></name>
<name><surname>Feldman</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Managing Rosacea: A Review of the Use of Metronidazole Alone and in Combination with Oral Antibiotics</article-title><source>J. Drugs Dermatol.</source><year>2007</year><volume>6</volume><fpage>495</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">17679183</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00168"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaitanya</surname><given-names>V.</given-names></name>
</person-group><article-title>Pawar, Nishant V. Pote, Munjaji M. Mule, Rohini B. Chougale, Ms. Wale R.R A Review On: Formulation and Estimation of Topical Emulgel</article-title><source>Int. J. Pharm. Sci.</source><year>2024</year><volume>2</volume><fpage>602</fpage><lpage>609</lpage></element-citation></ref><ref id="B34-pharmaceutics-17-00168"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>B.M.</given-names></name>
<name><surname>Kuchekar</surname><given-names>A.B.</given-names></name>
<name><surname>Pawar</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Emulgel Approach to Formulation Development: A Review</article-title><source>Biosci. Biotechnol. Res. Asia</source><year>2021</year><volume>18</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.13005/bbra/2931</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-00168"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zulfakar</surname><given-names>M.H.</given-names></name>
<name><surname>Pubadi</surname><given-names>H.</given-names></name>
<name><surname>Ibrahim</surname><given-names>S.I.</given-names></name>
<name><surname>Hairul</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Medium-Chain Triacylglycerols (MCTs) and Their Fractions in Drug Delivery Systems: A Systematic Review</article-title><source>J. Oleo Sci.</source><year>2024</year><volume>73</volume><fpage>293</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.5650/jos.ess23204</pub-id><pub-id pub-id-type="pmid">38432994</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00168"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thiboutot</surname><given-names>D.</given-names></name>
<name><surname>Anderson</surname><given-names>R.</given-names></name>
<name><surname>Cook-Bolden</surname><given-names>F.</given-names></name>
<name><surname>Draelos</surname><given-names>Z.</given-names></name>
<name><surname>Gallo</surname><given-names>R.L.</given-names></name>
<name><surname>Granstein</surname><given-names>R.D.</given-names></name>
<name><surname>Kang</surname><given-names>S.</given-names></name>
<name><surname>Macsai</surname><given-names>M.</given-names></name>
<name><surname>Gold</surname><given-names>L.S.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
</person-group><article-title>Standard Management Options for Rosacea: The 2019 Update by the National Rosacea Society Expert Committee</article-title><source>J. Am. Acad. Dermatol.</source><year>2020</year><volume>82</volume><fpage>1501</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.01.077</pub-id><pub-id pub-id-type="pmid">32035944</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00168"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sosa</surname><given-names>L.</given-names></name>
<name><surname>Calpena</surname><given-names>A.C.</given-names></name>
<name><surname>Silva-Abreu</surname><given-names>M.</given-names></name>
<name><surname>Espinoza</surname><given-names>L.C.</given-names></name>
<name><surname>Rinc&#x000f3;n</surname><given-names>M.</given-names></name>
<name><surname>Bozal</surname><given-names>N.</given-names></name>
<name><surname>Domenech</surname><given-names>O.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Lagunas</surname><given-names>M.J.</given-names></name>
<name><surname>Clares</surname><given-names>B.</given-names></name>
</person-group><article-title>Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>312</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11070312</pub-id><pub-id pub-id-type="pmid">31277267</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00168"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>M.K.</given-names></name>
<name><surname>Kumar Biswal</surname><given-names>P.</given-names></name>
</person-group><article-title>Complexation, Optimization, Formulation Development and Characterization of Clindamycin Phosphate Gel Using Zinc Acetate Dihydrate</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>2</volume><fpage>472</fpage><lpage>483</lpage></element-citation></ref><ref id="B39-pharmaceutics-17-00168"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar Trivedi</surname><given-names>M.</given-names></name>
</person-group><article-title>Spectroscopic Characterization of Biofield Treated Metronidazole and Tinidazole</article-title><source>Med. Chem.</source><year>2015</year><volume>5</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.4172/2161-0444.1000283</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-00168"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumari</surname><given-names>D.</given-names></name>
<name><surname>Karmakar</surname><given-names>V.</given-names></name>
<name><surname>Sisinthy</surname><given-names>S.P.</given-names></name>
<name><surname>Pandey</surname><given-names>M.</given-names></name>
<name><surname>Jain</surname><given-names>N.</given-names></name>
<name><surname>Gorain</surname><given-names>B.</given-names></name>
</person-group><article-title>Nanoemulsion and Nanoemulgel-Based Carriers as Advanced Delivery Tools for the Treatment of Oral Diseases</article-title><source>Drug Deliv. Transl. Res.</source><year>2024</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s13346-024-01735-2</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-00168"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Milutinov</surname><given-names>J.</given-names></name>
<name><surname>Krstono&#x00161;i&#x00107;</surname><given-names>V.</given-names></name>
<name><surname>&#x00106;irin</surname><given-names>D.</given-names></name>
<name><surname>Pavlovi&#x00107;</surname><given-names>N.</given-names></name>
</person-group><article-title>Emulgels: Promising Carrier Systems for Food Ingredients and Drugs</article-title><source>Polymers</source><year>2023</year><volume>15</volume><elocation-id>2302</elocation-id><pub-id pub-id-type="doi">10.3390/polym15102302</pub-id><pub-id pub-id-type="pmid">37242878</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00168"><label>42.</label><element-citation publication-type="gov"><article-title>Clindamycin: Uses, Interactions, Mechanism of Action|DrugBank Online</article-title><comment>Available online: <ext-link xlink:href="https://go.drugbank.com/drugs/DB01190" ext-link-type="uri">https://go.drugbank.com/drugs/DB01190</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-11">(accessed on 11 January 2025)</date-in-citation></element-citation></ref><ref id="B43-pharmaceutics-17-00168"><label>43.</label><element-citation publication-type="gov"><article-title>Metronidazole: Uses, Interactions, Mechanism of Action|DrugBank Online</article-title><comment>Available online: <ext-link xlink:href="https://go.drugbank.com/drugs/DB00916" ext-link-type="uri">https://go.drugbank.com/drugs/DB00916</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-11">(accessed on 11 January 2025)</date-in-citation></element-citation></ref><ref id="B44-pharmaceutics-17-00168"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caparica</surname><given-names>R.</given-names></name>
<name><surname>J&#x000fa;lio</surname><given-names>A.</given-names></name>
<name><surname>Fernandes</surname><given-names>F.</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>M.E.M.</given-names></name>
<name><surname>Costa</surname><given-names>J.G.</given-names></name>
<name><surname>Santos de Almeida</surname><given-names>T.</given-names></name>
</person-group><article-title>Upgrading the Topical Delivery of Poorly Soluble Drugs Using Ionic Liquids as a Versatile Tool</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>4338</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094338</pub-id><pub-id pub-id-type="pmid">33919354</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00168"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>N.</given-names></name>
<name><surname>Narang</surname><given-names>A.</given-names></name>
<name><surname>Bansal</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Use of Biorelevant Dissolution and PBPK Modeling to Predict Oral Drug Absorption</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>129</volume><fpage>222</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.05.024</pub-id><pub-id pub-id-type="pmid">29879527</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00168"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>B.</given-names></name>
<name><surname>Burgess</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Polymeric Materials in Drug Delivery</article-title><source>Natural and Synthetic Biomedical Polymers</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2014</year><fpage>333</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-396983-5.00021-1</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00168"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawant</surname><given-names>P.D.</given-names></name>
<name><surname>Luu</surname><given-names>D.</given-names></name>
<name><surname>Ye</surname><given-names>R.</given-names></name>
<name><surname>Buchta</surname><given-names>R.</given-names></name>
</person-group><article-title>Drug Release from Hydroethanolic Gels. Effect of Drug&#x02019;s Lipophilicity (Log P), Polymer&#x02013;Drug Interactions and Solvent Lipophilicity</article-title><source>Int. J. Pharm.</source><year>2010</year><volume>396</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.06.008</pub-id><pub-id pub-id-type="pmid">20540996</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00168"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva-Alvarez</surname><given-names>A.F.</given-names></name>
<name><surname>Ferreira</surname><given-names>M.P.</given-names></name>
<name><surname>Vicentini</surname><given-names>F.T.M.C.</given-names></name>
<name><surname>Pedrazzi</surname><given-names>V.</given-names></name>
<name><surname>de Freitas</surname><given-names>O.</given-names></name>
</person-group><article-title>A New Approach to Ex Vivo Permeation Studies in In-Situ Film-Forming Systems</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><fpage>257</fpage><pub-id pub-id-type="doi">10.1208/s12249-020-01799-6</pub-id><pub-id pub-id-type="pmid">32895787</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00168"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellison</surname><given-names>C.A.</given-names></name>
<name><surname>Tankersley</surname><given-names>K.O.</given-names></name>
<name><surname>Obringer</surname><given-names>C.M.</given-names></name>
<name><surname>Carr</surname><given-names>G.J.</given-names></name>
<name><surname>Manwaring</surname><given-names>J.</given-names></name>
<name><surname>Rothe</surname><given-names>H.</given-names></name>
<name><surname>Duplan</surname><given-names>H.</given-names></name>
<name><surname>G&#x000e9;ni&#x000e8;s</surname><given-names>C.</given-names></name>
<name><surname>Gr&#x000e9;goire</surname><given-names>S.</given-names></name>
<name><surname>Hewitt</surname><given-names>N.J.</given-names></name>
<etal/>
</person-group><article-title>Partition Coefficient and Diffusion Coefficient Determinations of 50 Compounds in Human Intact Skin, Isolated Skin Layers and Isolated Stratum Corneum Lipids</article-title><source>Toxicology Vitr.</source><year>2020</year><volume>69</volume><fpage>104990</fpage><pub-id pub-id-type="doi">10.1016/j.tiv.2020.104990</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-00168"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szunerits</surname><given-names>S.</given-names></name>
<name><surname>Boukherroub</surname><given-names>R.</given-names></name>
</person-group><article-title>Heat: A Highly Efficient Skin Enhancer for Transdermal Drug Delivery</article-title><source>Front. Bioeng. Biotechnol.</source><year>2018</year><volume>6</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2018.00015</pub-id><pub-id pub-id-type="pmid">29497609</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00168"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elewski</surname><given-names>B.E.</given-names></name>
</person-group><article-title>Percutaneous Absorption Kinetics of Topical Metronidazole Formulations in Vitro in the Human Cadaver Skin Model</article-title><source>Adv. Ther.</source><year>2007</year><volume>24</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/BF02849891</pub-id><pub-id pub-id-type="pmid">17565913</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00168"><label>52.</label><element-citation publication-type="webpage"><article-title>CIMA: CLINDAMICINA NORMON 300 Mg/2 Ml SOLUCION INYECTABLE EFG</article-title><comment>Available online: <ext-link xlink:href="https://cima.aemps.es/cima/publico/detalle.html?nregistro=63667" ext-link-type="uri">https://cima.aemps.es/cima/publico/detalle.html?nregistro=63667</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-26">(accessed on 26 October 2024)</date-in-citation></element-citation></ref><ref id="B53-pharmaceutics-17-00168"><label>53.</label><element-citation publication-type="webpage"><article-title>CIMA: METRONIDAZOL NORMON 250 Mg COMPRIMIDOS EFG</article-title><comment>Available online: <ext-link xlink:href="https://cima.aemps.es/cima/publico/detalle.html?nregistro=62223" ext-link-type="uri">https://cima.aemps.es/cima/publico/detalle.html?nregistro=62223</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-26">(accessed on 26 October 2024)</date-in-citation></element-citation></ref><ref id="B54-pharmaceutics-17-00168"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>S.R.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.</given-names></name>
<name><surname>Vaughn</surname><given-names>A.R.</given-names></name>
<name><surname>Notay</surname><given-names>M.</given-names></name>
<name><surname>Burney</surname><given-names>W.A.</given-names></name>
<name><surname>Sandhu</surname><given-names>S.</given-names></name>
<name><surname>Sivamani</surname><given-names>R.K.</given-names></name>
</person-group><article-title>The Skin and Gut Microbiome and Its Role in Common Dermatologic Conditions</article-title><source>Microorganisms</source><year>2019</year><volume>7</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms7110550</pub-id><pub-id pub-id-type="pmid">31717915</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00168"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zip</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Innovative Use of Topical Metronidazole</article-title><source>Dermatol. Clin.</source><year>2010</year><volume>28</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.det.2010.03.015</pub-id><pub-id pub-id-type="pmid">20510762</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00168"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Do&#x0011f;an</surname><given-names>A.</given-names></name>
<name><surname>&#x0015e;enkal</surname><given-names>S.</given-names></name>
<name><surname>Buruk&#x000e7;u</surname><given-names>D.</given-names></name>
<name><surname>Hayal</surname><given-names>T.B.</given-names></name>
<name><surname>K&#x00131;ratl&#x00131;</surname><given-names>B.</given-names></name>
<name><surname>&#x0015e;i&#x0015f;li</surname><given-names>H.B.</given-names></name>
<name><surname>Sa&#x0011f;ra&#x000e7;</surname><given-names>D.</given-names></name>
<name><surname>Asutay</surname><given-names>B.</given-names></name>
<name><surname>S&#x000fc;mer</surname><given-names>E.</given-names></name>
<name><surname>&#x0015e;ahin</surname><given-names>F.</given-names></name>
</person-group><article-title>3D Culture Of HaCaT Keratinocyte Cell Line as an in vitro Toxicity Model</article-title><source>Trak. Univ. J. Nat. Sci.</source><year>2022</year><volume>23</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.23902/trkjnat.1158811</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-00168"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Espinoza</surname><given-names>L.C.</given-names></name>
<name><surname>Silva-Abreu</surname><given-names>M.</given-names></name>
<name><surname>Calpena</surname><given-names>A.C.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Lagunas</surname><given-names>M.J.</given-names></name>
<name><surname>F&#x000e1;brega</surname><given-names>M.-J.</given-names></name>
<name><surname>Gardu&#x000f1;o-Ram&#x000ed;rez</surname><given-names>M.L.</given-names></name>
<name><surname>Clares</surname><given-names>B.</given-names></name>
</person-group><article-title>Nanoemulsion Strategy of Pioglitazone for the Treatment of Skin Inflammatory Diseases</article-title><source>Nanomedicine</source><year>2019</year><volume>19</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2019.03.017</pub-id><pub-id pub-id-type="pmid">31004811</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00168"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Dhalla</surname><given-names>N.S.</given-names></name>
</person-group><article-title>The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>1082</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25021082</pub-id><pub-id pub-id-type="pmid">38256155</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00168"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ta&#x0015f;-Aygar</surname><given-names>G.</given-names></name>
<name><surname>Cemil</surname><given-names>B.&#x000c7;.</given-names></name>
<name><surname>Ayd&#x00131;n</surname><given-names>F.N.</given-names></name>
<name><surname>Buran</surname><given-names>V.</given-names></name>
<name><surname>Kartal</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Serum Biomarkers IL-6 and HIF-1&#x003b1; in Rosacea: Assessing Their Significance in Disease Pathogenesis and Telangiectasia Formation</article-title><source>Dermatol. Pract. Concept.</source><year>2024</year><volume>14</volume><fpage>e2024267</fpage><pub-id pub-id-type="doi">10.5826/dpc.1404a267</pub-id><pub-id pub-id-type="pmid">39652912</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00168"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>D.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
</person-group><article-title>Signaling Pathways and Targeted Therapy for Rosacea</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1367994</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1367994</pub-id><pub-id pub-id-type="pmid">39351216</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00168"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kany</surname><given-names>S.</given-names></name>
<name><surname>Vollrath</surname><given-names>J.T.</given-names></name>
<name><surname>Relja</surname><given-names>B.</given-names></name>
</person-group><article-title>Cytokines in Inflammatory Disease</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>6008</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20236008</pub-id><pub-id pub-id-type="pmid">31795299</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00168"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Deng</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Exploring Metformin as a Candidate Drug for Rosacea through Network Pharmacology and Experimental Validation</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>174</volume><fpage>105971</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105971</pub-id><pub-id pub-id-type="pmid">34763093</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00168"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Deng</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>IL-6 Promotes Nuclear Translocation of HIF-1&#x003b1; to Aggravate Chemoresistance of Ovarian Cancer Cells</article-title><source>Eur. J. Pharmacol.</source><year>2021</year><volume>894</volume><fpage>173817</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173817</pub-id><pub-id pub-id-type="pmid">33345849</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00168"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>K.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
</person-group><article-title>Over Activation of IL-6/STAT3 Signaling Pathway in Juvenile Dermatomyositis</article-title><source>Rheumatol. Ther.</source><year>2024</year><volume>11</volume><fpage>1255</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1007/s40744-024-00699-6</pub-id><pub-id pub-id-type="pmid">39073510</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00168-f001"><label>Figure 1</label><caption><p>Schematic representation of the preparation of the MD-CM-gel, consisting of an aqueous phase and an oily phase that were combined, mixed, and homogenized.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f002"><label>Figure 2</label><caption><p>Visual observation of the MD-CM-gel at time 0, 3, and 6 months after its preparation.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f003"><label>Figure 3</label><caption><p>Microscopy images of MD-CM-gel at time 0, 3, and 6 months after its preparation.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f004"><label>Figure 4</label><caption><p>Extensibility of MD-CM-gel over 6 months. (<bold>a</bold>) Kinetic model for MD-CM-gel. (<bold>b</bold>) Statistical parameters.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f005"><label>Figure 5</label><caption><p>The droplet size of the MD-CM-gel. (<bold>a</bold>) time 0, (<bold>b</bold>) time 3 months, and (<bold>c</bold>) time 6 months.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f006"><label>Figure 6</label><caption><p>Rheograms of MD-CM-gel at (<bold>a</bold>) time 0 (<bold>b</bold>) 3 months and (<bold>c</bold>) 6 months after preparation (the red line corresponds to the flow curve (&#x003c4;) while the blue line represents the viscosity curve (&#x003b7;)).</p></caption><graphic xlink:href="pharmaceutics-17-00168-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f007"><label>Figure 7</label><caption><p>FTIR spectra of the MD-CM-gel, the blank emulgel and the drugs, MD and CM.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f008"><label>Figure 8</label><caption><p>Chemical structure of (<bold>a</bold>) CM, (<bold>b</bold>) MD and (<bold>c</bold>) Glycerine.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g008" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f009"><label>Figure 9</label><caption><p>Release profiles of CM and MD from the emulgel formulation. Both profiles fit the one-phase exponential association model.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g009" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f010"><label>Figure 10</label><caption><p>Permeation profiles of CM and MD through human skin from the emulgel formulation. The <bold>right</bold> panel shows the permeation profile for MD on a smaller scale for better visualization of the data.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g010" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f011"><label>Figure 11</label><caption><p>Inhibition halos generated on <italic toggle="yes">C.tuberculostearicum</italic> CECT 763. MD-gel: formulation with metronidazole; CM-gel: formulation with clindamycin; MD-CM-gel: formulation with MD and CM; Blank-gel: formulation without antimicrobial.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g011" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f012"><label>Figure 12</label><caption><p>Inhibition halos of commercial Formulations for <italic toggle="yes">C.tuberculostearicum</italic> CECT 763. CO1; formulation with 1% clindamycin. CO2; commercial formulation with 0.75% metronidazole.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g012" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f013"><label>Figure 13</label><caption><p>Cell viability of HaCaT keratinocytes after incubation for 24 h with the indicated compounds as single treatment (<bold>A</bold>) or in combination (<bold>B</bold>). To discard the toxicity effects of the vehicle (DMSO), cells were treated with DMSO at the final concentrations used to prepare the CM solutions. Cell viability was assayed by the MTT reduction method; 100% viability was set with the values obtained with the untreated control cells (indicated by a dotted line). Values represent the Mean &#x000b1; SD (n = 3). Statistical analysis one-way ANOVA Tukey&#x02018;s Multiple Comparison Test, * <italic toggle="yes">p</italic> &#x0003c; 0.05 versus control.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g013" position="float"/></fig><fig position="float" id="pharmaceutics-17-00168-f014"><label>Figure 14</label><caption><p>Anti-inflammatory action of MD in the absence and in the presence of CM in the LPS-INF&#x003b3; inflammation model. HaCat cells were incubated with MD at 0.3 &#x000b5;g/mL, in the absence or presence of CM at 0.2 &#x000b5;g/mL for 3 h and then, challenged with LPS-IFN&#x003b3; at 0.5 &#x000b5;g/mL and 0.02 &#x000b5;g/mL, respectively. In parallel, cells were incubated in the absence of LPS-IFN&#x003b3; as a control. Following 48 h incubation, IL6 secreted levels were measured by ELISA. Data are representative of 3 independent experiments. * <italic toggle="yes">p</italic> &#x0003c; 0.05 vs. untreated control cells; # <italic toggle="yes">p</italic> &#x0003c; 0.05 vs. LPS-INF&#x003b3; treated cells.</p></caption><graphic xlink:href="pharmaceutics-17-00168-g014" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00168-t001"><object-id pub-id-type="pii">pharmaceutics-17-00168-t001_Table 1</object-id><label>Table 1</label><caption><p>Composition of the emulgel formulation containing MD and CM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Quantity</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">MD</td><td align="left" valign="middle" rowspan="1" colspan="1">0.75%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CM</td><td align="left" valign="middle" rowspan="1" colspan="1">1%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Simulgel<sup>&#x000ae;</sup> 600</td><td align="left" valign="middle" rowspan="1" colspan="1">4.5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCT <sup>1</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">10%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Isohexadecane</td><td align="left" valign="middle" rowspan="1" colspan="1">5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Glycerine</td><td align="left" valign="middle" rowspan="1" colspan="1">5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Phenonip</td><td align="left" valign="middle" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified water</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">q.s.p. 73.45%</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> MCT = medium chain triglycerides.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t002"><object-id pub-id-type="pii">pharmaceutics-17-00168-t002_Table 2</object-id><label>Table 2</label><caption><p>Analytical conditions for the determination of MD and CM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MD Condition</th><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CM Condition</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Wavelength (nm)</td><td colspan="3" align="left" valign="middle" rowspan="1">318</td><td colspan="3" align="left" valign="middle" rowspan="1">210</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Flow (mL/min)</td><td colspan="3" align="left" valign="middle" rowspan="1">1.0</td><td colspan="3" align="left" valign="middle" rowspan="1">1.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Injection volume (&#x000b5;L)</td><td colspan="3" align="left" valign="middle" rowspan="1">50</td><td colspan="3" align="left" valign="middle" rowspan="1">50</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chromatography time</td><td colspan="3" align="left" valign="middle" rowspan="1">20</td><td colspan="3" align="left" valign="middle" rowspan="1">20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Retention time</td><td colspan="3" align="left" valign="middle" rowspan="1">7</td><td colspan="3" align="left" valign="middle" rowspan="1">7.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Eluent A</td><td colspan="3" align="left" valign="middle" rowspan="1">0.01 M KH<sub>2</sub>PO<sub>4</sub>, pH = 3.0</td><td colspan="3" align="left" valign="middle" rowspan="1">0.025 M KH<sub>2</sub>PO<sub>4</sub>, pH = 7.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Eluent B</td><td colspan="3" align="left" valign="middle" rowspan="1">MeOH; ACN</td><td colspan="3" align="left" valign="middle" rowspan="1">ACN</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Eluent C</td><td colspan="3" align="left" valign="middle" rowspan="1">MeOH</td><td colspan="3" align="left" valign="middle" rowspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gradient</td><td colspan="3" align="left" valign="middle" rowspan="1">
</td><td colspan="3" align="left" valign="middle" rowspan="1">
</td></tr><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time (min)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%C</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time (min)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0.0</td><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="left" valign="middle" rowspan="1" colspan="1">0.0</td><td align="left" valign="middle" rowspan="1" colspan="1">45</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">7.5</td><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="left" valign="middle" rowspan="1" colspan="1">8.0</td><td align="left" valign="middle" rowspan="1" colspan="1">45</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">9.0</td><td align="left" valign="middle" rowspan="1" colspan="1">18</td><td align="left" valign="middle" rowspan="1" colspan="1">24</td><td align="left" valign="middle" rowspan="1" colspan="1">9.0</td><td align="left" valign="middle" rowspan="1" colspan="1">70</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">13.0</td><td align="left" valign="middle" rowspan="1" colspan="1">18</td><td align="left" valign="middle" rowspan="1" colspan="1">24</td><td align="left" valign="middle" rowspan="1" colspan="1">13.0</td><td align="left" valign="middle" rowspan="1" colspan="1">70</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">14.5</td><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="left" valign="middle" rowspan="1" colspan="1">8</td><td align="left" valign="middle" rowspan="1" colspan="1">14.0</td><td align="left" valign="middle" rowspan="1" colspan="1">45</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.0</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.0</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>KH<sub>2</sub>PO<sub>4</sub>: Potassium dihydrogen phosphate; MeOH: methanol; ACN: acetonitrile.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t003"><object-id pub-id-type="pii">pharmaceutics-17-00168-t003_Table 3</object-id><label>Table 3</label><caption><p>MD-CM-gel pH values for over 6 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Time</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3 Months</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6 Months</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7 &#x000b1; 0.1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t004"><object-id pub-id-type="pii">pharmaceutics-17-00168-t004_Table 4</object-id><label>Table 4</label><caption><p>Data analysis for the rheograms of the MD-CM-gel at time 0, 3 months, and 6 months of preparation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Time <break/>(Months)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Viscosity Value<break/>at 100 s<sup>&#x02212;1</sup> (mPa.s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Flow</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Fitted</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ramp (Up/Down)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Thixotropy<break/>(Pa/s)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3052 &#x000b1; 23.59</td><td align="center" valign="middle" rowspan="1" colspan="1">Shear thinning</td><td align="center" valign="middle" rowspan="1" colspan="1">Cross</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9992/0.9999</td><td align="center" valign="middle" rowspan="1" colspan="1">23,470</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2879 &#x000b1; 48.56</td><td align="center" valign="middle" rowspan="1" colspan="1">Shear thinning</td><td align="center" valign="middle" rowspan="1" colspan="1">Cross</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9887/0.9997</td><td align="center" valign="middle" rowspan="1" colspan="1">21,520</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2901 &#x000b1; 43.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shear thinning</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9945/0.9998</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,770</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t005"><object-id pub-id-type="pii">pharmaceutics-17-00168-t005_Table 5</object-id><label>Table 5</label><caption><p>Drug release parameters from the emulgel according to a one-phase exponential association. Values represent Means &#x000b1; standard error (n = 6).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Best-Fit Values</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Metronidazole</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ymax (&#x000b5;g)</td><td align="left" valign="middle" rowspan="1" colspan="1">689.1 &#x000b1; 28.42</td><td align="left" valign="middle" rowspan="1" colspan="1">1628.0 &#x000b1; 66.77</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">K (h<sup>&#x02212;1</sup>)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.1387 &#x000b1; 0.0125</td><td align="left" valign="middle" rowspan="1" colspan="1">0.1813 &#x000b1; 0.0182</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Half-time (h)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.998</td><td align="left" valign="middle" rowspan="1" colspan="1">3.824</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9975</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9954</td></tr></tbody></table><table-wrap-foot><fn><p>Ymax = total amount of drug released; K = release rate constant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t006"><object-id pub-id-type="pii">pharmaceutics-17-00168-t006_Table 6</object-id><label>Table 6</label><caption><p>Permeation parameters: flux (<italic toggle="yes">Js</italic>), lag time (<italic toggle="yes">Tl</italic>), permeability coefficient (<italic toggle="yes">Kp</italic>), partition (<italic toggle="yes">P1</italic>), and diffusion (<italic toggle="yes">P2</italic>) coefficients drug amount retained in the skin (<italic toggle="yes">Qret</italic>) and plasma concentration at the steady-state (<italic toggle="yes">Css</italic>) of CM and MD after 31 h of in vitro permeation tests in human skin. The results are given in median (minimum and maximum).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Metronidazole</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Jss (&#x000b5;g/h)</td><td align="left" valign="middle" rowspan="1" colspan="1">18.44 </td><td align="left" valign="middle" rowspan="1" colspan="1">2.84</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(18.07&#x02013;19.53)</td><td align="left" valign="middle" rowspan="1" colspan="1">(2.20&#x02013;2.97)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tl (h)</td><td align="left" valign="middle" rowspan="1" colspan="1">7.00</td><td align="left" valign="middle" rowspan="1" colspan="1">3.64</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(6.14&#x02013;8.41)</td><td align="left" valign="middle" rowspan="1" colspan="1">(3.14&#x02013;4.85)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Kp (cm/h)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.00184</td><td align="left" valign="middle" rowspan="1" colspan="1">0.00038</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.00100&#x02013;0.00214)</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.00025&#x02013;0.00052)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P1 (cm)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.03717</td><td align="left" valign="middle" rowspan="1" colspan="1">0.000828</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.02264&#x02013;0.04854)</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.00019&#x02013;0.000914)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P2 (1/h)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.0496</td><td align="left" valign="middle" rowspan="1" colspan="1">0.0457</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.0391&#x02013;0.0511)</td><td align="left" valign="middle" rowspan="1" colspan="1">(0.0365&#x02013;0.0601)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Qret (&#x000b5;g/cm<sup>2</sup>)</td><td align="left" valign="middle" rowspan="1" colspan="1">6.46</td><td align="left" valign="middle" rowspan="1" colspan="1">13.34</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">(5.68&#x02013;7.32)</td><td align="left" valign="middle" rowspan="1" colspan="1">(10.61&#x02013;15.51)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Css (ng/mL)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.65</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.88</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t007"><object-id pub-id-type="pii">pharmaceutics-17-00168-t007_Table 7</object-id><label>Table 7</label><caption><p>MIC results in &#x000b5;g/mL of CM and MD separately and in combination for each of the strains.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Microorganism</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MIC Alone</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MIC in Combination</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC CM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC MD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC CM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC MD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium simulans</italic> DSM 44415</td><td align="center" valign="middle" rowspan="1" colspan="1">2.44</td><td align="center" valign="middle" rowspan="1" colspan="1">117.19</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22</td><td align="center" valign="middle" rowspan="1" colspan="1">58.59</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium tuberculostearicum</italic> CECT 763</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">937.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">468.75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cutibacterium acnes</italic> ATCC 6919</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">468.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">58.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic> ATCC 25922</td><td align="center" valign="middle" rowspan="1" colspan="1">19.53</td><td align="center" valign="middle" rowspan="1" colspan="1">1875</td><td align="center" valign="middle" rowspan="1" colspan="1">9.77</td><td align="center" valign="middle" rowspan="1" colspan="1">937.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Micrococcus luteus</italic> ATCC 10240</td><td align="center" valign="middle" rowspan="1" colspan="1">9.77</td><td align="center" valign="middle" rowspan="1" colspan="1">3750</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22</td><td align="center" valign="middle" rowspan="1" colspan="1">937.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> ATCC 29213</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">937.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0175</td><td align="center" valign="middle" rowspan="1" colspan="1">234.38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus capitis</italic> CECT 7101<sup>T</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">468.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">234.38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus epidermidis</italic> ATCC 12228 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">468.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">234.38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus hominis</italic> CECT 234<sup>T</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">468.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">234.38</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptococcus mitis</italic> ATCC 49456</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">234.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.59</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t008"><object-id pub-id-type="pii">pharmaceutics-17-00168-t008_Table 8</object-id><label>Table 8</label><caption><p>Diameter in mm of the inhibition halos originated by the different formulations: CM-gel: formulation with CM; MD-gel: formulation with metronidazole; MD-CM-gel: formulation with MD and CM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strains </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CM-gel</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MD-gel</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MD-CM-gel</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium simulans</italic> DSM 44415</td><td align="center" valign="middle" rowspan="1" colspan="1">39 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">13 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">45 &#x000b1; 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium tuberculostearicum</italic> CECT 763</td><td align="center" valign="middle" rowspan="1" colspan="1">44 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">48 &#x000b1; 0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cutibacterium acnes</italic> ATCC 6919</td><td align="center" valign="middle" rowspan="1" colspan="1">75 &#x000b1; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">11 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">70 &#x000b1; 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic> ATCC 25922</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">18 &#x000b1; 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Micrococcus luteus</italic> ATCC 10240</td><td align="center" valign="middle" rowspan="1" colspan="1">38 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">43 &#x000b1; 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> ATCC 29213</td><td align="center" valign="middle" rowspan="1" colspan="1">31 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">8 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">34 &#x000b1; 0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus capitis</italic> CECT 7101<sup>T</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">39 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">40 &#x000b1; 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus epidermidis</italic> ATCC 12228 </td><td align="center" valign="middle" rowspan="1" colspan="1">39 &#x000b1; 0</td><td align="center" valign="middle" rowspan="1" colspan="1">14 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">39 &#x000b1; 0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus hominis</italic> CECT 234<sup>T</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42 &#x000b1; 1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00168-t009"><object-id pub-id-type="pii">pharmaceutics-17-00168-t009_Table 9</object-id><label>Table 9</label><caption><p>Inhibition halos in mm of commercial solid formulations. CO1; Formulation with 1% clindamycin. CO2; Formulation with 0.75% metronidazole.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strains </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CO1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CO2</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium simulans</italic> DSM 44415</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Corynebacterium tuberculostearicum</italic> CECT 763</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Cutibacterium acnes</italic> ATCC 6919</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic> ATCC 25922</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Micrococcus luteus</italic> ATCC 10240</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> ATCC 29213</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus capitis</italic> CECT 7101<sup>T</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus epidermidis</italic> ATCC 12228 </td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus hominis</italic> CECT 234<sup>T</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></floats-group></article>